<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v56588e10vq.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
<TITLE>e10vq</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>Form&nbsp;10-Q</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt"><B>(Mark One)</B>
</DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 1px">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#254;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>


<!-- xbrl,dc -->
<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>For the quarterly period ended June&nbsp;30, 2010</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OR</B></DIV>


<DIV align="center">
<TABLE cellspacing="0" border="0" cellpadding="0" width="100%" style="font-size: 12pt">
<TR style="font-size: 6pt">
    <TD width="7%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD align="center"><FONT style="font-family: Wingdings">&#111;</FONT> </TD>
    <TD>&nbsp;</TD>
    <TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>
Commission file number 000-12477</B>
</DIV>

<DIV align="center" style="font-size: 20pt; margin-top: 10pt"><B>Amgen Inc.</B>
</DIV>

<DIV align="center" style="font-size: 8pt">
(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State or other jurisdiction of <BR>
incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>95-3540776</B><BR>
(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>One Amgen Center Drive, <BR>
Thousand Oaks, California</B><BR>
(Address of principal executive offices)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom"><B>91320-1799</B><BR>
(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>(805)&nbsp;447-1000</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed
by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or
for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90&nbsp;days. Yes <FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this chapter) during the preceding 12&nbsp;months
(or for such shorter period that the registrant was required to submit and post such files). Yes
<FONT style="font-family: Wingdings">&#254;</FONT> No <FONT style="font-family: Wingdings">&#111;</FONT>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, or a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the
Exchange Act. (Check one):
</DIV>



<DIV align="center">
<TABLE style="font-size: 10pt; text-align: justify" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="22%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Large accelerated filer <FONT style="font-family: Wingdings">&#254;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" nowrap>Non-accelerated filer <FONT style="font-family: Wingdings">&#111;</FONT><BR>
(Do not check if a smaller reporting company)
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>Smaller reporting company <FONT style="font-family: Wingdings">&#111;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of
the Exchange Act) Yes <FONT style="font-family: Wingdings">&#111;</FONT> No <FONT style="font-family: Wingdings">&#254;</FONT>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">As
of July&nbsp;30, 2010, the registrant had 958,474,477 shares of common stock, $0.0001 par value,
outstanding.
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>











<P align="center" style="font-size: 12pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INDEX</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->

<TR valign="bottom">
    <TD width="9%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page No.</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD  ALIGN="LEFT" colspan="3"><A href="#101"><B>PART I - FINANCIAL INFORMATION</B></A></TD>
    <TD>&nbsp;</TD>
    <TD align="right"><B>1</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">Item&nbsp;1.</A></DIV></TD>
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#102">FINANCIAL STATEMENTS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:25px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#103">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#104">CONDENSED CONSOLIDATED BALANCE SHEETS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#105">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#106">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:15px; text-indent:-15px"><A href="#107">Item&nbsp;2.</A></DIV></TD>

<TD align="left" valign="top"><DIV style="margin-left:15px; text-indent:-0px"><A href="#107">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#108">Item&nbsp;4.</A></DIV></TD>

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#108">CONTROLS AND PROCEDURES</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD  ALIGN="LEFT" colspan="3"><A href="#109"><B>PART II - OTHER INFORMATION</B></A></TD>
    <TD>&nbsp;</TD>
<TD align="right"><b>35</b></TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#110">Item&nbsp;1.</A></DIV></TD>

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#110">LEGAL PROCEEDINGS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#111">Item&nbsp;1A.</A></DIV></TD>

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#111">RISK FACTORS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#112">Item&nbsp;2.</A></DIV></TD>

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#112">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#113">Item&nbsp;6.</A></DIV></TD>

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px"><A href="#113">EXHIBITS</A></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
<TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD  ALIGN="LEFT" colspan="3"><DIV style="margin-left:15px; text-indent:-15px"><A href="#114">SIGNATURES</A></DIV></TD>
    <TD>&nbsp;</TD>
<TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD  ALIGN="LEFT" colspan="3"><A href="#115">INDEX TO EXHIBITS</A></TD>
    <TD>&nbsp;</TD>
<TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="v56588exv3w7.htm">EX-3.7</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="v56588exv10w11.htm">EX-10.11</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="v56588exv31.htm">EX-31 SECTION 302 CERTIFICATIONS</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="v56588exv32.htm">EX-32 SECTION 906 CERTIFICATIONS</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="amgn-20100630.xml">EX-101 INSTANCE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="amgn-20100630.xsd">EX-101 SCHEMA DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="amgn-20100630_cal.xml">EX-101 CALCULATION LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="amgn-20100630_lab.xml">EX-101 LABELS LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="amgn-20100630_pre.xml">EX-101 PRESENTATION LINKBASE DOCUMENT</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="amgn-20100630_def.xml">EX-101 DEFINITION LINKBASE DOCUMENT</A></FONT></TD></TR>
</TABLE>
</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>



<P align="center" style="font-size: 12pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART I &#151; FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FINANCIAL STATEMENTS</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.</B>
</DIV>

<DIV align="left">
<A name="103"></A>
</DIV>
<!-- xbrl,in -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF INCOME</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(In millions, except per share data)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,613</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,634</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,141</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,872</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">191</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">255</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,021</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cost of sales (excludes amortization of certain
acquired intangible assets presented below)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">531</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,008</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">675</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">693</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,321</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,326</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">986</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">910</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,870</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,708</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization of certain acquired intangible assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">147</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">147</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,256</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,398</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,243</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,517</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,457</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,778</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest expense, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">147</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">297</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest and other income, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">178</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income before income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,464</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,357</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,884</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,589</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Provision for income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">262</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">515</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">301</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,202</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,269</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,369</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,288</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Earnings per share:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.44</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.24</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.23</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shares used in calculation of earnings per share:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Basic</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">959</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,013</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">970</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,023</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Diluted</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">964</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,017</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">976</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,027</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">See accompanying notes.
</DIV>
<!-- /xbrl,in -->


<P align="center" style="font-size: 12pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.</B>
</DIV>

<DIV align="left">
<A name="104"></A>
</DIV>
<!-- xbrl,bs -->
<DIV align="center" style="font-size: 10pt"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(In millions, except per share data)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->

<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="center" colspan="9"><DIV style="margin-left:15px; text-indent:-15px"><B>ASSETS</B></DIV></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,712</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,884</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,811</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,558</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Trade receivables, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,208</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,109</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Inventories</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,112</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,220</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,321</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,161</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,164</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18,932</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Property, plant and equipment, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,630</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,738</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Intangible assets, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,421</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,567</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Goodwill</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,334</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,335</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,251</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,057</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">40,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">39,629</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 3pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" colspan="9"><DIV style="margin-left:15px; text-indent:-15px"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></DIV></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">722</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">574</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,856</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,299</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current portion of convertible notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,414</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,992</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,873</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Convertible notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,232</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,512</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other long-term debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,086</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,089</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other non-current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,320</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,488</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Contingencies and commitments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; equity:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Common stock and additional paid-in capital;
$0.0001 par value; 2,750 shares authorized;
outstanding - 958 shares in 2010 and
995 shares in 2009</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,119</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26,944</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated deficit</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,266</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4,322</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Accumulated other comprehensive income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">317</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,170</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,667</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">40,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">39,629</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">See accompanying notes.
</DIV>
<!-- /xbrl,bs -->


<P align="center" style="font-size: 12pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.</B>
</DIV>

<DIV align="left">
<A name="105"></A>
</DIV>
<!-- xbrl,cf -->

<DIV align="center" style="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</B></DIV>
<!-- xbrl,body -->

<DIV align="center" style="font-size: 10pt"><B>(In millions)</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Unaudited)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->

<TR valign="bottom">
    <TD width="75%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash flows from operating activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,369</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,288</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Depreciation and amortization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">503</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">520</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stock-based compensation expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">166</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">123</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other items, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">111</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Changes in operating assets and liabilities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Trade receivables, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(99</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(108</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Inventories</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(129</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(48</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accounts payable</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">148</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Accrued income taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(297</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(79</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Other accrued liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(376</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(367</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash provided by operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,477</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,538</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash flows from investing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Purchases of property, plant and equipment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(271</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(256</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Purchases of marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,607</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7,483</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from sales of marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,246</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,365</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Proceeds from maturities of marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">290</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">964</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(48</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(32</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash used in investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,390</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,442</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash flows from financing activities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Repurchases of common stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,300</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,997</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net proceeds from issuance of debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">989</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,980</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net proceeds from issuance of common stock in
connection with the Company&#146;s equity award programs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Net cash (used in) provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,259</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">(Decrease) increase in cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,172</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,194</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents at beginning of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,884</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,774</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents at end of period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,712</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,968</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">See accompanying notes.
</DIV>
<!-- /xbrl,cf -->




<P align="center" style="font-size: 12pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl,ns -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.</B>
</DIV>

<DIV align="left">
<A name="106"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 5pt"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 0pt"><B>June&nbsp;30, 2010</B></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 0pt"><B>(Unaudited)</B></DIV>



<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><B>1. Summary of significant accounting policies</B>
</DIV>

<!-- xbrl,body -->
<!-- xbrl,dnap,"Nature Of Operations" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Business</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Amgen
Inc. (including its subsidiaries, referred to as &#147;Amgen,&#148;
&#147;the Company,&#148; &#147;we,&#148; &#147;our&#148; or
&#147;us&#148;) is a global biotechnology medicines company that discovers, develops, manufactures and
markets medicines for grievous illnesses. We concentrate on innovating novel medicines based on
advances in cellular and molecular biology and we operate in one business segment, human
therapeutics.
</DIV>
<!-- /xbrl,dnap -->
<!-- xbrl,dnap,"Basis Of Presentation Policy" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Basis of presentation</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The financial information for the three and six months ended June&nbsp;30, 2010 and 2009 is
unaudited but includes all adjustments (consisting of only normal recurring adjustments, unless
otherwise indicated), which Amgen considers necessary for a fair
presentation of its consolidated results of operations for those periods. Interim results are not necessarily
indicative of results for the full fiscal year.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The condensed consolidated financial statements should be read in conjunction with our
consolidated financial statements and the notes thereto contained in our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2009 and our condensed consolidated financial statements in our
Quarterly Report on Form 10-Q for the three months ended March&nbsp;31, 2010.
</DIV>
<!-- /xbrl,dnap -->
<!-- xbrl,dnap,"Consolidation Policy" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Principles of consolidation</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The condensed consolidated financial statements include the accounts of Amgen as well as its
wholly owned subsidiaries. We do not have any significant interests in any variable interest
entities. All material intercompany transactions and balances have been eliminated in
consolidation.
</DIV>
<!-- /xbrl,dnap -->
<!-- xbrl,dnap,"Use Of Estimates Policy" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Use of estimates</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The preparation of condensed consolidated financial statements in conformity with accounting
principles generally accepted in the United States (&#147;GAAP&#148;) requires management to make estimates
and assumptions that affect the amounts reported in the condensed consolidated financial statements
and accompanying notes. Actual results may differ from those estimates.
</DIV>
<!-- /xbrl,dnap -->
<!-- xbrl,dnap,"Property Plant And Equipment Policy" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Property, plant and equipment, net</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation
of $4.9&nbsp;billion and $4.6&nbsp;billion as of June&nbsp;30, 2010 and December&nbsp;31, 2009, respectively.
</DIV>
<!-- /xbrl,dnap -->
<!-- xbrl,dnap,"Fair Value Measurement Policy" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Fair value measurement</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">In January&nbsp;2010, we adopted a newly issued accounting standard which requires additional
disclosure about the amounts of and reasons for significant transfers between levels of the fair
value hierarchy discussed in Note 8, <I>&#147;Fair value measurement.&#148; </I>This standard also clarifies
existing disclosure requirements related to the level of disaggregation of fair value measurements
for each class of assets and liabilities and disclosures about inputs and valuation techniques used
to measure fair value for both recurring and nonrecurring Level 2 and Level 3 measurements. As this
 accounting standard only requires enhanced disclosure, the adoption of this standard
did not impact our financial position, results of operations or cash flows. In addition, effective
for interim and annual periods beginning after December&nbsp;15, 2010, this standard will require
additional disclosure and require an entity to present disaggregated information about activity in
Level 3 fair value measurements on a gross basis, rather than a single amount.
</DIV>
<!-- /xbrl,dnap -->
<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>2. Income taxes</B>
</DIV>

<!-- xbrl,body -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The effective tax rates for the three and six months ended June&nbsp;30, 2010 and June&nbsp;30, 2009 are
different from the statutory rate primarily as a result of indefinitely invested earnings of our
foreign operations. In addition, the effective tax rates for the three and six months ended June
30, 2009 were further reduced by the favorable resolution of certain non-routine transfer pricing
matters with the Internal Revenue Service (&#147;IRS&#148;) for prior periods. We do not provide for U.S.
income taxes on undistributed earnings of our foreign operations that are intended to be invested
indefinitely outside the United States.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">One or more of our legal entities file income tax returns in the U.S. federal jurisdiction,
various U.S. state jurisdictions and certain foreign jurisdictions
and our income tax returns are
routinely audited by the tax authorities in those jurisdictions. Significant disputes can arise
with these tax authorities involving the timing and amount of deductions, the use of tax
credits and allocations of income among various tax jurisdictions because of differing
interpretations of tax laws and regulations. We are no
longer subject to U.S. federal income tax examinations for years ending on or before December
31, 2004 or to California state income tax examinations for years ending on or before December&nbsp;31,
2003.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The IRS is currently examining our U.S. income tax returns for the years ended December&nbsp;31,
2007 and 2008. As of June&nbsp;30, 2010, the Company and the IRS have agreed to certain transfer
pricing adjustments for the years ended December&nbsp;31, 2007 and 2008 and the Company has accordingly
adjusted its liability for unrecognized tax benefits (&#147;UTBs&#148;) as discussed below. The remainder of
this examination is expected to be completed in 2011.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">During the three and six months ended June&nbsp;30, 2010, the gross amount of our UTBs increased by
approximately $55&nbsp;million and $130&nbsp;million, respectively, as a result of tax positions taken during
the current year. During the three and six months ended June&nbsp;30, 2010, the gross amount of our
UTBs decreased by approximately $375&nbsp;million primarily as a result of resolving certain transfer
pricing matters related to prior years. Substantially all of our UTBs as of June&nbsp;30, 2010, if
recognized, would affect our effective tax rate. The Company does not expect any significant
changes to its UTBs during the next twelve months.
</DIV>

<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>3. Earnings per share</B>
</DIV>

<!-- xbrl,body -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The
computation of basic earnings per share (&#147;EPS&#148;) is based upon the weighted-average number of our common
shares outstanding. The computation of diluted EPS is based upon the weighted-average number of our common shares and
potential dilutive common shares outstanding. Potential common shares outstanding, determined using
the treasury stock method, principally include: stock options, restricted stock units and other
equity awards under our employee compensation plans; our 2011 Convertible Notes, 2013 Convertible
Notes and 2032 Modified Convertible Notes, as discussed below; and our outstanding warrants
(collectively &#147;dilutive securities&#148;). The convertible note hedges purchased in connection with the
issuance of our 2011 Convertible Notes and 2013 Convertible Notes are excluded from the calculation
of diluted EPS as their impact is always anti-dilutive.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Upon conversion of our 2011 Convertible Notes, 2013 Convertible Notes and 2032 Modified
Convertible Notes, the principal amount or accreted value would be settled in cash and the excess
of the conversion value, as defined, over the principal amount or accreted value may be settled in
cash and/or shares of our common stock. Therefore, only the shares of our common stock potentially
issuable with respect to the excess of the notes&#146; conversion value over their principal amount or
accreted value, if any, are considered as dilutive potential common shares for purposes of
calculating diluted EPS.
</DIV>
<!-- xbrl,dn,"Basic And Diluted Earning Per Share" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table sets forth the computation for basic and diluted EPS (in millions, except
per share information):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>

    <TD width="5%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>

    <TD width="5%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>

    <TD width="5%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Income (Numerator):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Net income for basic and diluted EPS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,202</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,269</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,369</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,288</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shares (Denominator):</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Weighted-average shares for basic EPS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">959</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,013</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">970</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,023</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Effect of dilutive securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Weighted-average shares for diluted EPS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">964</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,017</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">976</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,027</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Basic EPS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.44</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.24</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Diluted EPS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.23</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">For the three and six months ended June&nbsp;30, 2010, there were employee stock options,
calculated on a weighted average basis, to purchase 46&nbsp;million and 43&nbsp;million shares of our common
stock, respectively, with exercise prices greater than the average market prices of our common
stock for these periods that are not included in the computation of diluted EPS as their impact
would have been anti-dilutive. For the three and six months ended June&nbsp;30, 2009, there were
employee stock options, calculated on a weighted average basis, to purchase 51&nbsp;million and 48
million shares of our common stock, respectively, with exercise prices greater than the average
market prices of our common stock for these periods that are not included in the computation of
diluted EPS as their impact would have been anti-dilutive. In addition, shares of our common stock,
which may be issued upon conversion of our convertible debt or upon exercise of our warrants, are
not included in the computation of diluted EPS for any of the periods presented above as their impact on
diluted EPS would have been anti-dilutive. Shares which may be issued under our 2010 performance award plan were also excluded because
conditions under the plan were not met.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>


<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>4. Available-for-sale securities</B>
</DIV>
<!-- xbrl,body -->
<!-- xbrl,dn,"Fair Values Of Available For Sale Investments By Type Of Security" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The fair values of available-for-sale investments by type of security, contractual maturity
and classification in the Condensed Consolidated Balance Sheets are as follows (in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="53%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Estimated</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>fair</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>cost</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>gains</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>losses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>value</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Type of security:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Treasury securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,762</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,831</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other government related debt securities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Obligations of U.S. government agencies
and FDIC guaranteed bank debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,833</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,906</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Foreign and other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate debt securities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Financial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,680</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,715</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Industrial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,103</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,169</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">278</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">287</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mortgage and asset backed securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">701</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">705</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Money market mutual funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,544</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,544</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other short-term interest bearing securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total debt securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,136</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,408</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,186</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(22</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,449</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="53%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Estimated</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amortized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>fair</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>December 31, 2009</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>cost</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>gains</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>losses</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>value</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Type of security:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Treasury securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,929</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(6</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,935</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Obligations of U.S. government agencies
and FDIC guaranteed bank debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,731</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,792</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Corporate debt securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,193</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">96</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(4</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,285</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Mortgage and asset backed securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">489</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">491</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Money market mutual funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,784</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,784</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other short-term interest bearing securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total debt securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">174</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,342</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(8</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,244</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">174</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(21</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,397</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<!-- /xbrl,dn -->


<P align="center" style="font-size: 12pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>
<!-- xbrl,dn,"Fair Values Of Available For Sale Investments By Contractual Maturity" -->

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Contractual maturity</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Maturing in one year or less</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,187</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,444</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Maturing after one year through three years</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,860</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,369</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Maturing after three years through five years</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,841</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,207</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Maturing after five years</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">520</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">322</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total debt securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,408</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,342</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,449</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,397</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->
<!-- xbrl,dn,"Fair Values Of Available For Sale Investments By Classification In Consolidated Balance Sheets" -->
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Classification in the Condensed Consolidated Balance Sheets</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,712</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,884</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12,811</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,558</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other assets &#151; noncurrent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,564</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,497</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Less cash</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(115</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,449</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,397</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">For the three months ended June&nbsp;30, 2010 and 2009, realized gains totaled $36&nbsp;million and
$26&nbsp;million, respectively, and realized losses totaled $2&nbsp;million and $15&nbsp;million, respectively.
For the six months ended June&nbsp;30, 2010 and 2009, realized gains totaled $58&nbsp;million and $60
million, respectively, and realized losses totaled $3&nbsp;million and $48&nbsp;million, respectively. The
cost of securities sold is based on the specific identification method.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The primary objectives of our investment portfolio are liquidity and safety of principal.
Investments are made with the objective of achieving the highest rate of return consistent with
these two objectives. Our investment policy limits debt security investments to certain types of
debt and money market instruments issued by institutions primarily with investment grade credit
ratings and places restrictions on maturities and concentration by type and issuer.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We review our available-for-sale securities for other-than-temporary declines in fair value
below their cost basis on a quarterly basis and whenever events or changes in circumstances
indicate that the cost basis of an asset may not be recoverable. This evaluation is based on a
number of factors including, the length of time and extent to which
the fair value has been below our cost basis and adverse conditions specifically related to the security including any
changes to the credit rating of the security by a rating agency. As of June&nbsp;30, 2010 and December
31, 2009, we believe that the cost bases for our available-for-sale securities were recoverable in
all material respects.
</DIV>

<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>5. Inventories</B>
</DIV>

<!-- xbrl,body -->
<!-- xbrl,dn,"Inventories" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Inventories consisted of the following (in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->

<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>


<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Raw materials</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">127</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">97</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Work in process</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,521</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,683</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Finished goods</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">464</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">440</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,112</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,220</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<P align="center" style="font-size: 12pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>

<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>6. Financing arrangements</B>
</DIV>

<!-- xbrl,body -->
<!-- xbrl,dn,"Schedule Of Debt Instruments" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table reflects the carrying value of our borrowings under our various financing
arrangements (dollar amounts in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR>
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">0.125% convertible notes due February&nbsp;2011 (2011 Convertible Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,414</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,342</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">0.375% convertible notes due 2013 (2013 Convertible Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,088</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">5.85% notes due 2017 (2017 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,099</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,099</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4.85% notes due 2014 (2014 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">5.70% notes due 2019 (2019 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6.40% notes due 2039 (2039 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">996</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">995</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6.375% notes due 2037 (2037 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">899</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">5.75% notes due 2040 (2040 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">696</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6.15% notes due 2018 (2018 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">6.90% notes due 2038 (2038 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">4.50% notes due 2020 (2020 Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Zero-coupon modified convertible notes due in 2032 (2032 Modified
Convertible Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">8.125% notes due 2097 (Other)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total borrowings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,732</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,601</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Less current portion (2011 Convertible Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,414</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total non-current debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,318</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,601</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>2020 Notes and 2040 Notes</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">In March&nbsp;2010, we issued $700&nbsp;million aggregate principal amount of notes due in 2040 (the
&#147;2040 Notes&#148;) and $300&nbsp;million aggregate principal amount of notes due in 2020 (the &#147;2020 Notes&#148;)
in a registered offering. The 2040 Notes and 2020 Notes pay interest at fixed annual rates of 5.75%
and 4.50%, respectively. The 2040 Notes and 2020 Notes may be redeemed at any time at our option,
in whole or in part, at an amount equal to the outstanding principal amount of the notes being
redeemed plus accrued and unpaid interest, if any, and a &#147;make-whole&#148; amount, as defined. Upon the
occurrence of a change in control triggering event, as defined, we
may be required to purchase, for
cash, all or a portion of the 2040 Notes and the 2020 Notes at a price equal to 101% of the
principal amount of the notes plus accrued and unpaid interest. Debt
issuance costs incurred in connection with the issuance of this debt totaled
approximately $7&nbsp;million and are being amortized over the lives of the notes.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>2017 Notes</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">In March&nbsp;2010, we entered into interest rate swap agreements that effectively convert a fixed
rate interest coupon to a London Interbank Offered Rate
(&#147;LIBOR&#148;)-based floating rate coupon over the remaining life of the 2017
notes.
</DIV>



<P align="center" style="font-size: 12pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>


<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>7. Stockholders&#146; equity</B>
</DIV>

<!-- xbrl,body -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Stock repurchase program</I>
</DIV>

<!-- xbrl,dn,"Stock Repurchase Program" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">A summary of activity under our stock repurchase program is as follows (in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Dollars</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Dollars</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">First quarter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,684</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,997</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Second quarter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">616</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,997</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">In December&nbsp;2009, the Board of Directors authorized us to repurchase up to an additional $5.0
billion of common stock of which a total of $3.7&nbsp;billion remains available for stock repurchases as
of June&nbsp;30, 2010. The manner of purchases, the amount we spend and the number of shares repurchased
will vary based on a variety of factors, including the stock price, blackout periods in which we
are restricted from repurchasing shares, and our credit rating and may include private block
purchases as well as market transactions.
</DIV>

<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>8. Fair value measurement</B>
</DIV>

<!-- xbrl,body -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We use various valuation approaches in determining the fair value of our financial assets and
liabilities within a hierarchy that maximizes the use of observable inputs and minimizes the use of
unobservable inputs by requiring that observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability based on market
data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect
the Company&#146;s assumptions about the inputs that market participants would use in pricing the asset
or liability and are developed based on the best information available in the circumstances. The
fair value hierarchy is broken down into three levels based on the source of inputs as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 10pt">
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Level 1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="text-align: justify">Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company
has the ability to access</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Level 2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Valuations for which all significant inputs are observable, either directly or indirectly, other than level 1 inputs</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Level 3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&#151;
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The availability of observable inputs can vary among the various types of financial assets and
liabilities. To the extent that the valuation is based on models or inputs that are less observable
or unobservable in the market, the determination of fair value requires more judgment. In certain
cases, the inputs used to measure fair value may fall into different levels of the fair value
hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value
hierarchy within which the fair value measurement is categorized is based on the lowest level of
input used that is significant to the overall fair value measurement.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>
<!-- xbrl,dn,"Fair Value Measurement Inputs Disclosure" -->

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; text-indent: 8%">The following fair value hierarchy tables present information about each major class/category
of the Company&#146;s financial assets and liabilities measured at fair value on a recurring basis (in
millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>Fair value measurement at June 30, 2010 using:</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Quoted prices in</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>active markets for</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>&nbsp;&nbsp;other observable&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unobservable&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>identical assets</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>inputs</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>inputs</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 1)</B></TD>
    <TD>&nbsp;</TD>
        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 2)</B></TD>
    <TD>&nbsp;</TD>
        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 3)</B></TD>
    <TD>&nbsp;</TD>
        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Assets:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Available-for-sale securities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">U.S. Treasury securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,831</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,831</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Other government related debt securities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Obligations of U.S. <BR>
government agencies
and <BR>
FDIC guaranteed bank debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,906</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,906</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Foreign and other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:75px; text-indent:-15px">Total other government related debt securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,904</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,904</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Corporate debt securities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Financial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,715</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,715</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Industrial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,169</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,169</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">287</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:75px; text-indent:-15px">Total corporate debt securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,171</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,171</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Mortgage and asset backed securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">705</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">705</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Money market mutual funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,544</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,544</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Other short-term interest bearing securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:75px; text-indent:-15px">Total available-for-sale securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,416</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,033</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,449</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Derivatives:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">328</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">328</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Interest rate swap contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">214</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">214</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:75px; text-indent:-15px">Total derivatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">542</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">542</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR><TD style="font-size: 3pt">&nbsp;</TD></TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,416</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,991</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Liabilities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Derivatives:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">46</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:75px; text-indent:-15px">Total derivatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">46</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="45%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="14" style="border-bottom: 1px solid #000000"><B>Fair
value measurement at December 31, 2009 using:</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Quoted prices in</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Significant</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>active markets for</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>&nbsp;&nbsp;other observable&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unobservable&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>identical assets</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>inputs</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>inputs</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 1)</B></TD>
    <TD>&nbsp;</TD>
        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 2)</B></TD>
    <TD>&nbsp;</TD>
        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(Level 3)</B></TD>
    <TD>&nbsp;</TD>
        <TD>&nbsp;</TD>
<TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Assets:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Available-for-sale securities:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">U.S. Treasury securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,935</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,935</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD nowrap><DIV style="margin-left:45px; text-indent:-15px">Obligations of U.S. government <BR>
agencies
and FDIC <BR>
guaranteed bank debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,792</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,792</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Corporate debt securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,285</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Mortgage and asset backed securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">491</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">491</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Money market mutual funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,784</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,784</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Other short-term interest bearing securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Equity securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total available-for-sale securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,774</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8,623</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,397</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Derivatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">153</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">153</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,774</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">8,776</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,550</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="font-size: 5pt"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><B>Liabilities:</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Derivatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">152</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">152</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">152</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">152</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:45px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<!-- /xbrl,dn -->
<P align="center" style="font-size: 12pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>



<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Our U.S. Treasury securities, money market mutual funds and equity securities are valued
using quoted market prices in active markets with no valuation adjustment. We value our U.S.
Treasury securities and money market mutual funds taking into consideration valuations obtained
from a third-party pricing service.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Substantially all of our other government related and corporate debt securities are investment
grade with maturity dates of five years or less. Our government related debt securities portfolio
is comprised of securities with a weighted average credit rating of &#147;AAA&#148; or equivalent by Standard
and Poor&#146;s (&#147;S&#038;P&#148;), Moody&#146;s Investors Services, Inc. (&#147;Moody&#146;s&#148;) or Fitch, Inc. (&#147;Fitch&#148;), and our
corporate debt securities portfolio has a weighted average credit rating of &#147;A&#148; or equivalent by
S&#038;P, Moody&#146;s or Fitch. We value these securities taking into consideration valuations obtained from
third-party pricing services. The pricing services utilize industry standard valuation models,
including both income and market based approaches, for which all
significant inputs are observable,
either directly or indirectly, to estimate fair value. These inputs include reported trades and
broker/dealer quotes of the same or similar securities, issuer credit spreads, benchmark securities
and other observable inputs.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Our mortgage and asset backed securities portfolio is comprised entirely of senior tranches,
with a credit rating of &#147;AAA&#148; or equivalent by S&#038;P, Moody&#146;s or Fitch. We value these securities
taking into consideration valuations obtained from third-party pricing services. The pricing
services utilize industry standard valuation models, including both income and market based
approaches, for which all significant inputs are observable, either directly or indirectly, to
estimate fair value. These inputs include reported trades and broker/dealer quotes of the same or
similar securities, issuer credit spreads, benchmark securities, prepayment/default projections
based on historical data and other observable inputs.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We value our other short-term interest bearing securities at amortized cost which approximates
fair value given their near term maturity dates.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Substantially all of our foreign currency forward and option contracts have maturities of
three years or less and all are entered into with counterparties that have a minimum credit rating
of &#147;A-&#148; or equivalent by S&#038;P, Moody&#146;s or Fitch. We value these securities taking into
consideration valuations obtained from a third-party valuation service that utilizes an
income-based industry standard valuation model for which all
significant inputs are observable,
either directly or indirectly, to estimate fair value. These inputs include quoted foreign currency
spot rates, forward points, LIBOR and swap curves and obligor credit default swap rates. In
addition, inputs for our foreign currency option contracts also include implied volatility
measures. These inputs, where applicable, are at commonly quoted intervals. As of June&nbsp;30, 2010 and
December&nbsp;31, 2009, we had open foreign currency forward contracts with notional amounts of $3.2
billion and $3.4&nbsp;billion, respectively, and open option contracts with notional amounts of $419
million and $376&nbsp;million, respectively, that were primarily Euro-based and were designated as cash
flow hedges. In addition, as of June&nbsp;30, 2010 and December&nbsp;31, 2009, we had $566&nbsp;million and $414
million, respectively, of foreign currency forward contracts to reduce exposure to fluctuations in
value of certain assets and liabilities denominated in foreign
currencies that were primarily Euro-based and that were not
designated as hedges (see Note 9, <I>&#147;Derivative
instruments&#148;</I>).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Our interest rate swap contracts are entered into with counterparties that have a minimum
credit rating of &#147;A-&#148; or equivalent by S&#038;P, Moody&#146;s or Fitch. We value these contracts using an
income-based industry standard valuation model for which all
significant inputs are observable,
either directly or indirectly, to estimate fair value. These inputs include LIBOR and swap curves
and obligor credit default swap rates. We had interest rate swap agreements with an aggregate
notional amount of $2.6&nbsp;billion and $1.5&nbsp;billion as of
June&nbsp;30, 2010 and December&nbsp;31, 2009,
respectively, that were designated as fair value hedges (see Note 9, <I>&#147;Derivative
instruments&#148;</I>).
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">There have been no transfers of assets or liabilities between the fair value measurement
levels and there were no material remeasurements to fair value during the six months ended June&nbsp;30,
2010 and 2009 of assets and liabilities that are not measured at fair value on a recurring basis.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 12pt"><I>Summary of the fair value of other financial instruments</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>Short-term assets and liabilities</I>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The estimated fair values of cash equivalents, accounts receivable and accounts payable
approximate their carrying values due to the short-term nature of these financial instruments.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>Borrowings</I>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following tables present the carrying values and estimated fair values of our convertible
notes, modified convertible notes and other long-term notes payable. We value our convertible and
modified convertible notes using an income-based industry standard valuation model for which all
significant inputs are observable, either directly or indirectly, including benchmark yields
adjusted for our credit risk, to estimate fair value (Level 2). We value our other long-term notes
using quoted prices (Level 2).<!-- xbrl,dn,"Carrying Value And Estimated Fair Value Of Our Convertible Notes Modified Convertible Notes And Other Notes" -->
<FONT style="font-size: 10pt; font-family: 'Times New Roman',Times,serif"> The fair values of our convertible notes and modified convertible notes
exclude their equity components and represent only the liability
</FONT></DIV>
<P align="center" style="font-size: 12pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">
<FONT style="font-size: 10pt; font-family: 'Times New Roman',Times,serif">components of these instruments as their equity
components are included in &#147;Common stock and additional paid-in capital&#148; in the Condensed
Consolidated Balance Sheets (in millions):
</FONT>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt; font-family: 'Times New Roman',Times,serif" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="71%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30, 2010</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Carrying value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Fair value&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2011 Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,414</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,491</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2013 Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,451</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2017 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,099</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,275</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2014 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,116</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2019 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,160</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2039 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">996</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,175</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2037 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,036</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2040 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">696</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">761</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2018 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">587</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2038 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">619</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2020 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">321</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2032 Modified Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">135</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">11,732</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,210</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt; font-family: 'Times New Roman',Times,serif" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="71%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>December 31, 2009</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Carrying value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Fair value&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2011 Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,342</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,487</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2013 Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,088</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,374</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2017 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,099</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,207</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2014 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,075</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2019 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,077</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2039 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">995</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,102</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2037 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">988</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2018 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">551</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2038 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">582</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2032 Modified Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">125</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,601</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">11,649</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<!-- /xbrl,dn -->
<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>9. Derivative instruments</B>
</DIV>

<!-- xbrl,body -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The Company is exposed to risks related to its business operations, certain of which are
managed through derivative instruments. The risks that we manage by using derivative instruments
are foreign exchange rate risk and interest rate risk. We use financial instruments including
foreign currency forward, foreign currency option, forward interest rate and interest rate swap
contracts to reduce our risk to these exposures. We do not use derivatives for speculative trading
purposes.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We recognize all of our derivative instruments as either assets or liabilities at fair value
in the Condensed Consolidated Balance Sheets (see Note 8, &#147;<I>Fair value measurement</I>&#148;). The accounting
for changes in the fair value of a derivative instrument depends on whether it has been formally
designated and qualifies as part of a hedging relationship under the applicable accounting
standards and, further, on the type of hedging relationship. For derivatives formally designated as
hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives are
highly effective in offsetting changes in either the fair value or cash flows of the hedged item.
Our derivatives that are not designated and do not qualify as hedges are adjusted to fair value
through current earnings.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Cash flow hedges</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We are exposed to possible changes in values of certain anticipated foreign currency cash
flows resulting from changes in foreign currency exchange rates, primarily associated with our
international product sales denominated in Euros. Increases or decreases in the cash flows
associated with our international product sales due to movements in foreign currency exchange rates
are partially offset by the corresponding increases and decreases in our international operating
expenses resulting from these foreign currency exchange rate movements. To further reduce our
exposure to foreign currency exchange rate fluctuations on our international product sales, we
enter into foreign currency forward and option contracts to hedge a portion of our projected
international product sales primarily over a three-year time horizon with, at any given point in
time, a higher percentage of nearer term projected product
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">sales being hedged than successive
periods. As of June&nbsp;30, 2010 and December&nbsp;31, 2009, we had open foreign currency forward contracts
 with notional amounts of $3.2&nbsp;billion and $3.4&nbsp;billion, respectively, and
open option contracts with notional amounts of $419&nbsp;million and $376&nbsp;million, respectively. These
foreign currency forward and option contracts,
primarily Euro-based, have been designated as cash flow hedges, and
accordingly, the effective portion of the unrealized gains and losses on these contracts are
reported in Accumulated Other Comprehensive Income (&#147;AOCI&#148;) in the Condensed Consolidated Balance
Sheets and reclassified to earnings in the same periods during which the hedged transactions affect
earnings.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">In connection with the anticipated issuance of long-term fixed-rate debt, we occasionally
enter into forward interest rate contracts in order to hedge the variability in cash flows due to
changes in the applicable Treasury rate between the time we enter into these contracts and the time
the related debt is issued. Gains and losses on such contracts, which are designated as cash flow
hedges, are recorded in Other Comprehensive Income (&#147;OCI&#148;) and amortized into earnings over the
lives of the associated debt issuances.
</DIV>
<!-- xbrl,dn,"Effective Portion Of Unrealized Gain Loss Recognized In Other Comprehensive Income For Our Cash Flow Hedge Contracts" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table reflects the effective portion of the unrealized gain/(loss) recognized in
OCI for our cash flow hedge contracts (in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->

<TR valign="bottom">
    <TD width="27%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>


<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD colspan="3" nowrap align="center" style="border-bottom: 1px solid #000000"><B>Derivatives in cash flow hedging relationships</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">399</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(77</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Forward interest rate contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(11</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">224</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(100</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">399</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(88</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->
<!-- xbrl,dn,"Statements Of Income And Effective Portion Of Gain Loss Reclassified From Accumulated Other Comprehensive Income Into Income For Our Cash Flow Hedge Contracts" -->


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table reflects the location in the Condensed Consolidated Statements of Income
and the effective portion of the gain/(loss) reclassified from AOCI
into earnings for our cash flow
hedge contracts (in millions):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="27%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center"><B>Derivatives
in cash flow</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">

<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>hedging relationships</B></TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Statements of</B> <B>income location</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Product sales</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">29</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Forward interest rate contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="white-space: nowrap">Interest expense, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">29</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">No portions of our cash flow hedge contracts are excluded from the assessment of hedge
effectiveness and the ineffective portions of these hedging instruments resulted in approximately
$1&nbsp;million of income recorded in &#147;Interest and other income, net&#148; in the Condensed Consolidated
Statements of Income for both the three and six months ended June&nbsp;30, 2010. The ineffective
portions of these hedging instruments resulted in an aggregate expense of approximately $1&nbsp;million
recorded in &#147;Interest and other income, net&#148; and &#147;Interest expense, net&#148; in the Condensed
Consolidated Statements of Income for both the three and six months ended June&nbsp;30, 2009. As of June
30, 2010, the amounts expected to be reclassified from AOCI into
earnings over the next 12&nbsp;months are
approximately $130&nbsp;million of gains on foreign currency forward and option contracts and
approximately $1&nbsp;million of losses on forward interest rate contracts.
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Fair value hedges</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">To achieve a desired mix of fixed and floating interest rate debt, we have entered into
interest rate swap agreements, which qualify and have been designated as fair value hedges. The
terms of these interest rate swap agreements correspond to the related hedged debt instruments and
effectively convert a fixed interest rate coupon to a LIBOR-based floating rate coupon over the
lives of the respective notes. We had interest rate swap agreements with aggregate notional amounts
of $2.6&nbsp;billion and $1.5&nbsp;billion as of June&nbsp;30, 2010 and December&nbsp;31, 2009, respectively. The
interest rate swap agreements as of June&nbsp;30, 2010 were for our notes due in 2014, 2017 and 2018
and, as of December&nbsp;31, 2009 for our notes due in 2014 and 2018. For derivative instruments that
are designated and qualify as a fair value hedge, the unrealized gain or loss on the derivative as
well as the offsetting unrealized loss or gain on the hedged item attributable to the hedged risk
are recognized in current earnings. For the three and six months ended June&nbsp;30, 2010, we
included the unrealized losses on the hedged debt of $107&nbsp;million and $124&nbsp;million,
respectively, in the same line item, &#147;Interest expense, net&#148; in the Condensed Consolidated
Statements of Income, as the offsetting unrealized gains of $107&nbsp;million and $124&nbsp;million,
respectively, on the related interest rate swap agreements. For the three and six months ended June
30, 2009, we included the unrealized gains on the hedged debt of $41&nbsp;million and $103&nbsp;million,
respectively, in the same line item, &#147;Interest expense, net&#148; in the Condensed Consolidated
Statements of Income, as the offsetting unrealized losses of $41&nbsp;million and $103&nbsp;million,
respectively, on the related interest rate swap agreements.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Derivatives not designated as hedges</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">We enter into foreign currency forward contracts to reduce our exposure to foreign currency
fluctuations of certain assets and liabilities denominated in foreign currencies which are not
designated as hedging transactions. These exposures are hedged on a month-to-month basis. As of
June&nbsp;30, 2010 and December&nbsp;31, 2009, the total notional amounts of these foreign currency forward
contracts, primarily Euro-based, were $566&nbsp;million and $414&nbsp;million, respectively.
</DIV>
<!-- xbrl,dn,"Statements Of Income And Amount Of Gain Recognized In Income For Derivative Instruments Not Designated As Hedging Instruments" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following table reflects the location in the Condensed Consolidated Statements of Income
and the amount of gain (loss)&nbsp;recognized in income for the derivative instruments not designated as
hedging instruments (in millions):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->

<TR valign="bottom">
    <TD width="27%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD></TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Three months ended</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6"><B>Six months ended</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" colspan="1" style="border-bottom: 0px solid #000000"><B>Derivatives not designated as</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>June 30,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>hedging instruments</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">&nbsp;&nbsp;&nbsp;<B>Statements of income location</B>&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><FONT style="white-space: nowrap">Interest and other income, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(10</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">76</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Classification in the Condensed Consolidated Balance Sheets</I>
</DIV>

<!-- xbrl,dn,"Fair Values Of Both Derivatives Designated As Hedging Instruments And Not Designated As Hedging Instruments Included In Condensed Consolidated Balance Sheets" -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">The following tables reflect the fair values of both derivatives designated as hedging
instruments and not designated as hedging instruments included in the Condensed Consolidated
Balance Sheets as of June&nbsp;30, 2010 and December&nbsp;31, 2009 (in millions):
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="4" style="border-bottom: 1px solid #000000"><B>Derivative assets</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="4" style="border-bottom: 1px solid #000000"><B>Derivative liabilities</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Balance Sheet location</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fair value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Balance Sheet location</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fair value</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD colspan="13" align="left"><DIV style="margin-left:15px; text-indent:-15px"><B>Derivatives designated as
hedging<br> instruments as of June&nbsp;30, 2010:</B></div></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:15px; text-indent:-15px">Interest rate swap contracts</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="margin-left:15px; text-indent:-15px">Other
current assets/<BR>
Other non-current <BR>
assets</div></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">214</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" nowrap><DIV style="margin-left:15px; text-indent:-15px">Accrued
liabilities/<BR>
Other non-current <BR>
liabilities</div></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" nowrap><DIV style="margin-left:15px; text-indent:-15px">Other
current assets/<BR>
Other non-current <BR>
assets</div></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">328</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top" nowrap><DIV style="margin-left:15px; text-indent:-15px">Accrued
liabilities/<BR>
Other non-current <BR>
liabilities</div></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total
derivatives designated as<br> hedging
instruments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">542</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD colspan="13" align="left"><DIV style="margin-left:15px; text-indent:-15px"><B>Derivatives not designated as
hedging<br> instruments as of June&nbsp;30, 2010:</B></div></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other current assets</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Accrued liabilities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total derivatives not designated as
<BR>hedging instruments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total derivatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">542</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">46</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 12pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B></DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="33%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="6%" nowrap>&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="4" style="border-bottom: 1px solid #000000"><B>Derivative assets</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="4" style="border-bottom: 1px solid #000000"><B>Derivative liabilities</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Balance Sheet location</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fair value</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Balance Sheet location</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fair value</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">

<TD colspan="13" align="left"><DIV style="margin-left:15px; text-indent:-15px"><B>Derivatives
designated as hedging<br> instruments as of December&nbsp;31, 2009:</B></DIV></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:15px; text-indent:-15px">Interest rate swap contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:15px; text-indent:-15px">Other current assets/<BR>
Other non-current<BR>
 assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:15px; text-indent:-15px">Accrued liabilities/<BR>
Other non-current <BR>
liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD valign="top"><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:15px; text-indent:-15px">Other current assets/<BR>
Other non-current <BR>
assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="margin-left:15px; text-indent:-15px">Accrued liabilities/<BR>
Other non-current<BR>
 liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">152</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total derivatives designated as<br> hedging
instruments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">153</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">152</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD colspan="13" align="left"><DIV style="margin-left:15px; text-indent:-15px"><B>Derivatives not designated as
hedging<br> instruments as of December&nbsp;31, 2009:</B></DIV></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Foreign exchange contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Other current assets</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Accrued liabilities</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total
derivatives not designated as<br>
hedging instruments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:60px; text-indent:-15px">Total derivatives</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">153</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">152</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<!-- /xbrl,dn -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Our derivative contracts that were in a liability position as of June&nbsp;30, 2010 contain
certain credit risk related contingent provisions that are triggered if (i)&nbsp;we were to undergo a
change in control and (ii)&nbsp;our or the surviving entity&#146;s creditworthiness deteriorates, which is
generally defined as having either a credit rating that is below investment grade or a materially
weaker creditworthiness after the change in control. If these events were to occur, the
counterparties would have the right, but not the obligation, to close the contracts under early
termination provisions. In such circumstances, the counterparties could request immediate
settlement of these contracts for amounts that approximate the then current fair values of the
contracts.
</DIV>

<!-- xbrl,n -->
<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>10. Contingencies and commitments</B>
</DIV>

<!-- xbrl,body -->

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">In the ordinary course of business, we are involved in various legal proceedings and other
matters, including those discussed in this Note, which are complex in nature and have outcomes that
are difficult to predict. We record accruals for such contingencies to the extent that we conclude
that it is probable that a liability will be incurred and the amount of the related loss can be
reasonably estimated. While it is not possible to accurately predict or determine the eventual
outcome of these items, one or more of these items currently pending could have a material adverse
effect on our consolidated results of operations, financial position or cash flows.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Certain of our legal proceedings and other matters are discussed below:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Teva Matters</I>

</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>Sensipar</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> Abbreviated New Drug Application (&#147;ANDA&#148;) Litigation</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On July&nbsp;16, 2010, the U.S. District Court for the District of Delaware (the &#147;Delaware District
Court&#148;) vacated its previous scheduling order, including the September&nbsp;1, 2010 date for the case to
enter the trial pool. The Delaware District Court entered a new scheduling order directed to
expert discovery and notifying the parties that after August&nbsp;31, 2010 the court will schedule
another status conference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Simonian v. Amgen Inc.</I>

</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On June&nbsp;8, 2010 the U.S. District Court for the Northern District of Illinois granted Amgen&#146;s
motion to stay the case. A status hearing has been scheduled for September&nbsp;16, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Average Wholesale Price (&#147;AWP&#148;) Litigation</I>

</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>State of Kansas, ex rel Steve Six v. Amgen Inc. and Immunex Corporation.</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On May&nbsp;16, 2010, Amgen and Immunex reached a settlement with the state of Kansas, and, on May
24, 2010, both companies were dismissed from the matter.
</DIV>




<P align="center" style="font-size: 12pt"><!-- Folio -->16<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<!-- xbrl -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.<BR>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Birch v. Sharer, et al.</I>

</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On June&nbsp;30, 2010, Amgen filed its demurrer to plaintiff&#146;s complaint with the Complex Division
of the Los Angeles Superior Court. The court will hear oral argument on the parties&#146; demurrers on
September&nbsp;13, 2010.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>ERISA Litigation</I>

</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On June&nbsp;16, 2010, the U.S. District Court for the Central District of California entered an
order dismissing the entire lawsuit with prejudice. On June&nbsp;24, 2010, the plaintiffs filed a
notice of appeal with the U.S. Court of Appeals for the Ninth Circuit. Petitioner&#146;s opening brief
and excerpts of record shall be served and filed by December&nbsp;6, 2010, and respondent&#146;s answering
brief and excerpts of record shall be served and filed by January&nbsp;5, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Qui Tam Actions</I>

</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On May&nbsp;7, 2010, the relator filed two motions with the U.S. District Court for the District of
Massachusetts (the &#147;Massachusetts District Court&#148;), one for reconsideration of the Massachusetts
District Court&#146;s dismissal and one for leave to file an amended complaint. On May&nbsp;26, 2010, the
Massachusetts District Court denied the relator&#146;s motion for reconsideration but granted leave to
file a fourth amended complaint. On May&nbsp;24, 2010, the states of New York, Massachusetts, Michigan,
California, Illinois, and Indiana (the &#147;States&#148;) filed notices of intent to appeal
the Massachusetts District Court&#146;s judgment to the U.S. Court of Appeals for the First
Circuit. On June&nbsp;9, 2010, the States filed a motion for certification under rule 54(b) to ensure
that they have an appealable order and the Massachusetts District Court granted the motion. On
June&nbsp;11, 2010, the Massachusetts District Court held a scheduling conference related to relator&#146;s
fourth amended complaint and ordered that a jury trial be set for the running trial list starting
on July&nbsp;5, 2011. On June&nbsp;28, 2010, Amgen filed motions to dismiss five non-conspiracy counts and
one conspiracy count in the relator&#146;s fourth amended complaint and a hearing on the motions to
dismiss was held by the Massachusetts District Court on July&nbsp;21, 2010. Following oral argument,
the Massachusetts District Court denied, from the bench, Amgen&#146;s motions to dismiss and indicated
that a written ruling would follow.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Other</I>

</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>Eastern District of New York Subpoenas</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Amgen continues to cooperate with the government&#146;s document requests. Additionally, numerous
current and former Amgen employees have and continue to receive civil and grand jury subpoenas to
provide testimony on a wide variety of subjects.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%"><I>Western District of Washington Subpoenas</I>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Amgen continues to cooperate with the government&#146;s document requests. Additionally, numerous
current and former Amgen employees, including some executive vice presidents and other officers of
the Company, have and continue to receive grand jury subpoenas to provide testimony on a wide
variety of subjects.
</DIV>

<!-- /xbrl,ns -->



<P align="center" style="font-size: 12pt"><!-- Folio -->17<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD  align="left" nowrap><B>Item&nbsp;2.</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Forward looking statements</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">This
report and other documents we file with the Securities and Exchange Commission (&#147;SEC&#148;) contain forward looking statements that
are based on current expectations, estimates, forecasts and projections about us, our future
performance, our business or others on our behalf, our beliefs and our management&#146;s assumptions. In
addition, we, or others on our behalf, may make forward looking statements in press releases or
written statements, or in our communications and discussions with investors and analysts in the
normal course of business through meetings, webcasts, phone calls and conference calls. Words such
as &#147;expect,&#148; &#147;anticipate,&#148; &#147;outlook,&#148; &#147;could,&#148; &#147;target,&#148; &#147;project,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe,&#148;
&#147;seek,&#148; &#147;estimate,&#148; &#147;should,&#148; &#147;may,&#148; &#147;assume,&#148; &#147;continue,&#148; variations of such words and similar
expressions are intended to identify such forward looking statements. These statements are not
guarantees of future performance and involve certain risks, uncertainties and assumptions that are
difficult to predict. We describe our respective risks, uncertainties and assumptions that could
affect the outcome or results of operations in &#147;<I>Item&nbsp;1A. Risk Factors</I>&#148; in Part&nbsp;II herein. We have
based our forward looking statements on our management&#146;s beliefs and assumptions based on
information available to our management at the time the statements are made. We caution you that
actual outcomes and results may differ materially from what is expressed, implied or forecast by
our forward looking statements. Reference is made in particular to forward looking statements
regarding product sales, regulatory activities, clinical trial results, reimbursement, expenses,
EPS, liquidity and capital resources and trends. Except as required under the federal securities
laws and the rules and regulations of the SEC, we do not have any intention or obligation to update
publicly any forward looking statements after the distribution of this report, whether as a result
of new information, future events, changes in assumptions or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Overview</B>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The following Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations (&#147;MD&#038;A&#148;) is intended to assist the reader in understanding Amgen&#146;s business. MD&#038;A is
provided as a supplement to, and should be read in conjunction with,
our Annual Report on Form 10-K for the year ended December 31,
2009 and our subsequent
Quarterly Reports on Form&nbsp;10-Q, including this report. Our results of operations
discussed in MD&#038;A are presented in conformity with GAAP.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We are the largest independent biotechnology medicines company. We discover, develop,
manufacture and market medicines for grievous illnesses. We concentrate on innovating novel
medicines based on advances in cellular and molecular biology. Our mission is to serve patients. We
operate in one business segment &#151; human therapeutics. Therefore, our results of operations are
discussed on a consolidated basis.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We operate in a highly regulated industry and various U.S. and foreign regulatory bodies have
substantial authority over how we conduct our business. Government authorities in the United States
and in other countries regulate the manufacturing and marketing of our products and our ongoing
research and development (&#147;R&#038;D&#148;) activities. In recent years, the regulatory environment has
evolved and there has been increased scrutiny on drug safety and increased authority being granted
to regulatory bodies, in particular the U.S. Food and Drug Administration (&#147;FDA&#148;), to assist in
ensuring the safety of therapeutic products. This has and may, in the future, lead to: fewer
products being approved by the FDA or other regulatory bodies; delays in receiving approvals;
additional safety-related requirements; restrictions on the use of products, including expanded
safety labeling, or required risk management activities, including a risk evaluation and mitigation
strategy (&#147;REMS&#148;); or other FDA compliance actions related to the promotion and sale of our
products and/or additional or more extensive clinical trials as part of post-marketing commitments
(&#147;PMCs&#148;), post-marketing requirements or a pharmacovigilance program. This is increasingly true of
new therapies with novel mechanisms of action. While these therapies may offer important benefits
and/or better treatment alternatives, they may also involve relatively new or a higher level of
scientific complexity and, therefore, generate increased safety concerns. Further, safety signals,
trends, adverse events (&#147;AEs&#148;) or results from clinical trials, including sub-analyses, studies or
meta-analyses (a meta-analysis is the review of studies using various statistical methods to
combine results from previous separate, but related, studies) performed by us or by others
(including our licensees or independent investigators) or from the marketed use of our products may
also result in similar additional safety-related requirements or restrictions on the use of our
products.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Most patients receiving our products for approved indications are covered by either government
or private payer healthcare programs which have pursued and continue to pursue aggressive cost
containment initiatives, including increased focus on comparing the effectiveness, benefits and
costs of similar treatments. In addition, governments may regulate access to, prices or
reimbursement levels of our products to control costs or to affect levels of use of our products,
and private insurers may be influenced by government reimbursement methodologies. Worldwide use of
our products may be affected by these cost containment pressures and cost shifting from governments
and private insurers to healthcare providers or patients in response to ongoing initiatives to
reduce or reallocate
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">healthcare expenditures, such as the recently enacted U.S. healthcare
legislation, which will have a material adverse impact on our business, as discussed further below.
In addition, the current worldwide economic conditions, including significant escalation of
budgetary constraints confronting many governments, have brought increased focus in the area of
costs containment. For example, while mandatory price reductions are a recurring aspect of business
for the pharmaceutical and biotechnology industries in the European Union (&#147;EU&#148;), many governments
in the EU have recently discussed, and continue to explore, options to further reduce healthcare
costs. As a result, we may experience mandatory price reductions that are more significant, more
frequent or initiated by more countries than our past experience, which may also negatively impact
our business. Therefore, sales of our principal products have and will continue to be affected by
the availability and extent of reimbursement from third-party payers, including government and
private insurance plans, and administration of those programs.

</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Currently, we market primarily recombinant protein therapeutic products in supportive cancer
care, nephrology and inflammation. Our principal products currently
include Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (darbepoetin alfa),
EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
(Epoetin alfa),
Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
(pegfilgrastim),
NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (Filgrastim) and ENBREL (etanercept), all of which are sold in
the United States. ENBREL is marketed under a co-promotion agreement with Pfizer Inc. (&#147;Pfizer&#148;) in
the United States and Canada. Our international product sales consist principally of European sales
of Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and
EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> stimulate the production of red blood cells to treat anemia and belong to a
class of drugs referred to as erythropoiesis-stimulating agents (&#147;ESAs&#148;). Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> is
used for the treatment of anemia both in supportive cancer care and in nephrology for both patients
on dialysis and not on dialysis. EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> is used in the dialysis setting to treat anemia
associated with chronic renal failure (&#147;CRF&#148;). Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
selectively stimulate the production of neutrophils, a type of white blood cell that helps the body
fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (&#147;TNF&#148;) by
inhibiting its binding to TNF receptors, a substance induced in response to inflammatory diseases,
such as rheumatoid arthritis and psoriasis. For both the three and
six months ended June&nbsp;30, 2010,
our principal products represented 92% of worldwide product sales,
and for both the three and  six months ended
June&nbsp;30, 2009, our principal products represented 93% of worldwide product sales.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">During the three months ended June&nbsp;30, 2010, we also began selling Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP>
(denosumab), a human monoclonal antibody that specifically targets RANK Ligand, an essential
regulator of osteoclasts (the cells that break down bone). In addition, our other marketed products
include the following:
Sensipar<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/Mimpara<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (cinacalcet), a small molecule calcimimetic that
lowers serum calcium levels; Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (panitumumab), a fully human monoclonal antibody
that binds specifically to the epidermal growth factor receptor; and  Nplate<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (romiplostim),
a thrombopoietin (&#147;TPO&#148;) receptor agonist that mimics endogenous TPO, the primary driver of
platelet production. For additional information about our products, their approved indications and
where they are marketed, see &#147;<I>Item&nbsp;1. Business &#151; Marketed Products and Selected Product
Candidates</I>&#148; in Part&nbsp;I of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2009 and
the discussion below with respect to Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP>.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Our U.S. product sales are subject to certain influences throughout the year, including,
wholesaler and end-user buying patterns (e.g. holiday-driven wholesaler and end-user stocking,
contract-driven buying and patients purchasing products later in the year after satisfying their
annual insurance deductibles). These factors can result in higher demand for our products and/or
higher wholesaler distributor inventory levels and, therefore, higher product sales for a given
three-month period, generally followed by a reduction in demand and/or a drawdown in wholesaler
inventories and a corresponding decline in product sales in the subsequent three- month period.
Typically, sales of our products in the United States for the three months ended March&nbsp;31 have been
slightly lower relative to the immediately preceding three month period, which we believe to be
due, in part, to certain of these factors. During the three months ended June&nbsp;30, sales of certain
of our products, most notably ENBREL, generally increase relative to the three months ended March
31 as patients work through their annual deductibles. These effects have generally not been significant when comparing product sales in the three
months ended March&nbsp;31 and June&nbsp;30 with product sales in the corresponding periods of the prior
year. However, we believe that the decline in product sales for the three months ended March&nbsp;31,
2009 was more pronounced due to the effects of the adverse economic environment.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Selected Financial Data</B><BR>
(dollar amounts in millions, except per share)

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 1px solid #000000"><B>Three months ended June 30,</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="15" style="border-bottom: 1px solid #000000"><B>Six months ended June 30,</B></TD>

</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000"><B>Change</B></TD>


</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Product sales:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">U.S.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,787</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,833</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(46</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,464</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">5,335</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">129</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">International</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">826</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">801</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,677</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">140</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">9</TD>
    <TD nowrap>&nbsp;%</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,613</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,634</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(21</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,141</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,872</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">269</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">191</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">79</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">112</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">255</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">149</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">106</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD nowrap>&nbsp;%</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:45px; text-indent:-15px">Total revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,021</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">375</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">5</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,256</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,398</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,243</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">155</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,202</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,269</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(67</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,369</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,288</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">81</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Diluted earnings per share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2.23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">9</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Total revenues for the three and six months ended June&nbsp;30, 2010 increased $91&nbsp;million,
or 2%, and $375&nbsp;million, or 5%, respectively, over the prior year periods. For the three months
ended June&nbsp;30, 2010, the increase in total revenues was due to an increase in other revenues of
$112&nbsp;million, substantially all of which relates to certain milestone payments earned from
GlaxoSmithKline plc (&#147;GSK&#148;) in connection with the approval and launch of Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> in the
EU and from Takeda Pharmaceutical Company Limited for the approval of Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in
Japan, partially offset by a decline in worldwide product sales of $21&nbsp;million, or 1%, discussed
below. For the six months ended June&nbsp;30, 2010, the increase in total revenues was primarily due to
an increase in worldwide product sales of $269&nbsp;million, or 4%, discussed below, and, to a lesser
extent, an increase in other revenues of $106&nbsp;million, primarily resulting from the milestone
payments earned in the three months ended June&nbsp;30, 2010.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">U.S. product sales for the three and six months ended June&nbsp;30, 2010 decreased $46&nbsp;million, or
2%, and increased $129&nbsp;million, or 2%, respectively, over the prior year periods. The decline in
U.S. product sales for the three months ended June&nbsp;30, 2010 was driven by an overall decline in
demand, primarily attributable to Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, slightly offset by favorable changes in
wholesaler inventories. The increase in U.S. product sales for the six months ended June&nbsp;30, 2010
was primarily attributable to favorable changes in wholesaler inventories and, to a lesser extent,
a net increase in demand as the decline in demand for Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> was more than offset by
an increase in demand for our other products. The favorable changes in wholesaler inventories which
occurred during the six months ended June&nbsp;30, 2010 are largely attributable to the significant
decline in these inventories that occurred in the three months ended March&nbsp;31, 2009, which we
believe was as a result of the adverse economic environment. Wholesaler inventories generally
remained at these reduced levels during the three months ended June&nbsp;30, 2009.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">International product sales for the three and six months ended June&nbsp;30, 2010 increased $25
million, or 3%, and $140&nbsp;million, or 9%, respectively, over the prior year periods. These increases
were primarily due to the launches of Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, Mimpara<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and Nplate<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> into
existing international markets and the favorable impact of foreign currency exchange rate changes
of $11&nbsp;million and $50&nbsp;million for the three and six months ended June&nbsp;30, 2010, respectively.
Excluding the impact of foreign currency exchange rate changes, international product sales for the
three and six months ended June&nbsp;30, 2010 increased 2% and 6%, respectively.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Our operating expenses for the three and six months ended June&nbsp;30, 2010 increased by $31
million, or 1%, and $155&nbsp;million, or 4%, respectively, over the prior year periods. These increases
were primarily as a result of increased selling, general and administrative (&#147;SG&#038;A&#148;) expenses of
$76&nbsp;million and $162&nbsp;million, respectively, in part due to increased spending activities in
anticipation of the approval and launch of Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP>. The increase in SG&#038;A expenses in the
three months ended June&nbsp;30, 2010 was partially offset by $49&nbsp;million of charges in the three months
ended June&nbsp;30, 2009 for certain cost savings initiatives and legal matters for which there were no
corresponding charges in the three months ended June&nbsp;30, 2010.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For the three and six months ended June&nbsp;30, 2010, net income decreased $67&nbsp;million,
or 5%, and increased $81&nbsp;million, or 4%, respectively, over the prior year periods. Net income for
the three months ended June&nbsp;30, 2010 decreased primarily as a result of a $115&nbsp;million income tax
benefit recognized in the three months ended June&nbsp;30, 2009 as a result of the favorable resolution
of certain non-routine transfer pricing matters with the IRS for prior periods (the &#147;IRS tax
settlement&#148;), partially offset by higher operating income
for the three months ended June&nbsp;30, 2010, discussed above. Net income for the six months ended June
30, 2010 increased primarily as a result of higher operating income, discussed above, partially
offset by the IRS tax settlement recognized in the three months ended June&nbsp;30, 2009. Diluted EPS
was unchanged at $1.25 for the three months ended June&nbsp;30, 2010 and 2009 as the reduction in net
income for the three months ended June&nbsp;30, 2010 was offset by the reduction in the number of shares
used in the calculation of diluted  EPS (964&nbsp;million shares compared to 1,017&nbsp;million shares for the
three months ended June&nbsp;30, 2010 and 2009, respectively). Diluted EPS was $2.43 for the six months
ended June&nbsp;30, 2010, representing an increase of 9%, over the prior year period which also
benefitted from a reduction in the number of shares used in the calculation of diluted
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:0%">EPS (976
million shares compared to 1,027&nbsp;million shares for the six months ended June&nbsp;30, 2010 and 2009,
respectively.) The decrease in the number of shares used in the computations of diluted EPS
reflects the impact of our stock repurchase program, including approximately 10&nbsp;million and 39
million shares which were repurchased in the three and six months ended June&nbsp;30, 2010,
respectively, at a total cost of $616&nbsp;million and $2.3&nbsp;billion, respectively.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">As of June&nbsp;30, 2010, cash, cash equivalents and marketable securities totaled $14.5&nbsp;billion,
our total debt outstanding was $11.7&nbsp;billion and our stockholders&#146; equity aggregated $23.2&nbsp;billion.
In addition, our cash flow from operations for the six months ended June&nbsp;30, 2010 was $2,477
million, representing a 2% decrease over the corresponding prior year period. Capital expenditures
for the six months ended June&nbsp;30, 2010 and 2009 were approximately $271&nbsp;million and $256&nbsp;million,
respectively. We believe that existing funds, cash generated from operations and existing sources
of and access to financing are adequate to satisfy our working capital, capital expenditure and
debt service requirements for the foreseeable future, including the repayment of our 2011
Convertible Notes with a principal balance of $2.5&nbsp;billion due in February&nbsp;2011. Of our total cash,
cash equivalents and marketable securities balance as of June&nbsp;30, 2010, approximately $12.3&nbsp;billion
was generated from operations in foreign tax jurisdictions and is held outside the U.S. and is
intended for use in our foreign operations. If these funds were repatriated for use in our U.S.
operations, we would be required to pay additional U.S. federal and state income taxes at the
applicable marginal tax rates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Key developments</B>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The following is a list of selected key developments that occurred during 2010 affecting our
business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>U.S. Healthcare Reform</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In March&nbsp;2010, the Patient Protection and Affordable Care Act (the &#147;PPACA&#148;) and the companion
Healthcare and Education Reconciliation Act, which made certain changes and adjustments to the
PPACA, primarily with respect to the PPACA&#146;s financial and budgetary impacts, were signed into law.
We refer to these two laws collectively as the &#147;new healthcare reform law.&#148; The new healthcare
reform law imposes additional costs on and reduces revenue for companies in the biotechnology and
pharmaceutical industries. The following paragraphs describe certain of the provisions of the new
healthcare reform law that will affect Amgen and our business.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Added Costs</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The new healthcare reform law increases the rebates we pay to the states for our products that
are covered and reimbursed by state Medicaid programs. See &#147;<I>Government Regulation&#151;Other</I>&#148; in Part&nbsp;I
of our Annual Report on Form 10-K for the year ended December&nbsp;31, 2009. The healthcare reform law
increases the minimum base Medicaid rebate rate payable on our products reimbursed by Medicaid from
15.1% to 23.1% of the Average Manufacturer Price (&#147;AMP&#148;) of the product, or if it is greater, the
difference between the AMP and the best price available from us to any non-exempt customer. The
change in the minimum rebate percentage was effective as of January&nbsp;1, 2010. (During the six months
ended June&nbsp;30, 2010, our U.S. product sales were negatively impacted by $21&nbsp;million related to this
provision of the new healthcare reform law.) The healthcare reform law also extends the Medicaid
drug rebate program to patients in Medicaid managed care insurance plans for whom rebates were not
previously required. The extension of rebates to patients in Medicaid managed care plans was
effective on March&nbsp;23, 2010. (During the six months ended June&nbsp;30, 2010, our U.S. product sales
were negatively impacted by $31&nbsp;million related to this provision of the new healthcare reform
law.) In addition, the healthcare reform law changes how the AMP is calculated by excluding certain
clinics and hospitals from the calculation, which is expected to increase the AMP for our products
reimbursed by Medicaid programs. An increase to our products&#146; AMP also increases the amount of the
rebates we pay to state Medicaid programs covering such products. The change to the AMP definition
will become effective on October&nbsp;1, 2010.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The new healthcare reform law also expands the list of provider institutions to which we must
extend discounts under the Public Health Service (&#147;PHS&#148;) 340B drug pricing program. The PHS pricing
program requires that we extend discounts comparable to the Medicaid rebate to a variety of
community health clinics and other entities that receive health services grants from the PHS, as
well as hospitals that serve a disproportionate share of Medicare and Medicaid beneficiaries. The
new healthcare reform law adds certain cancer centers, children&#146;s hospitals and rural hospitals to
the list of entities to which these discounts must be extended. This change to the list of eligible
entities was effective as of January&nbsp;1, 2010. (During the six months ended June&nbsp;30, 2010, our U.S.
product sales were negatively impacted by $17&nbsp;million related to this provision of the new
healthcare reform law.)
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The healthcare reform law also imposes a new fee on manufacturers and importers of &#147;branded
prescription drugs,&#148; which includes drugs approved under section 505(b) of the Federal Food, Drug,
and Cosmetic Act or biologicals licensed under section 351(a) of the Public Health Service Act.
Beginning in 2011, the new healthcare reform law sets an aggregate annual fee, to be paid by these
manufacturers and importers, totaling $28&nbsp;billion over ten years, of which $2.5&nbsp;billion is payable
in 2011. This annual fee will be apportioned among the participating companies, including Amgen,
based on each company&#146;s sales of qualifying products to, and
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">utilization by, certain U.S.
government programs during the preceding calendar year. This fee is not deductible for U.S. federal
income tax purposes. This additional fee will become effective January&nbsp;1, 2011. Manufacturers and
importers of generic or biosimilar drugs are not subject to the fee.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The
new law also requires manufacturers, like us, to provide a 50% discount to Medicare Part&nbsp;D
patients whose prescription expenses exceed the Part&nbsp;D prescription drug coverage limit but have
not yet reached the catastrophic coverage threshold. This coverage gap is sometimes referred to as
the Part&nbsp;D &#147;doughnut hole.&#148; This provision becomes effective January&nbsp;1, 2011.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Other Relevant Provisions</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The new healthcare reform law expands the Medicaid eligibility to include those with incomes
up to 133% of the federal poverty level (&#147;FPL&#148;), from 100% of the FPL. This provision becomes
effective January&nbsp;1, 2014.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The new healthcare reform law also authorizes the FDA to approve biosimilar products. The new
law establishes a period of 12&nbsp;years of data exclusivity for reference products in order to
preserve incentives for future innovation and outlines statutory criteria for science-based
biosimilar approval standards that take into account patient safety considerations. Under this
framework, data
exclusivity protects the data in the innovator&#146;s regulatory application by prohibiting others,
for a period of 12&nbsp;years, from gaining FDA approval based in part on reliance or reference to the
innovator&#146;s data in their application to the FDA. The new law does not change the duration of
patents granted on biologic products. While the FDA now has the authority to approve biosimilar
products, the FDA has not announced whether it will first publish guidance or rules for biosimilar
applicants before approving biosimilar products. With the resulting likely introduction of
biosimilars in the United States, we may in the future face greater competition from biosimilar
products, including from biosimilar manufacturers with approved products in Europe that may seek to
quickly obtain U.S. approval now that a regulatory pathway for biosimilars has been enacted,
subject to our ability to enforce our patents.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The U.S. healthcare reform legislation signed into law in March&nbsp;2010 will impact the revenue
we earn on sales of certain of our products more than others depending on where they are used, who
they are prescribed to and how they are reimbursed. Total U.S. product sales for the three months
ended June&nbsp;30, 2010 were adversely impacted by $45&nbsp;million for the provisions of the new healthcare
reform law that were in effect during this period, partially offset by $9&nbsp;million of favorable
changes in accounting estimates with respect to related accruals
recorded in the the three months ended March 31, 2010. For
the six months ended June&nbsp;30, 2010, total U.S. product sales were adversely impacted by $69&nbsp;million
for the provisions of the new healthcare reform law. We currently anticipate that the full year
impact of the new healthcare reform law will be approximately $200&nbsp;million to $250&nbsp;million for
2010. As additional provisions of the new healthcare reform law are implemented and certain other
provisions only in effect for part of 2010 become effective for the full year, we anticipate that
the future annual impact will increase significantly. As a result, we expect that the new
healthcare reform law, taken as a whole, will have a material adverse effect on our business and
results of operations. Estimating the aggregate financial impact resulting from the new healthcare
reform law is highly complex and is dependent on a number of factors, such as our estimated sales
volume and mix of products eligible for the rebates and discounts, the number of patients and
provider institutions now eligible for rebates and discounts (for example, Medicaid managed care
organizations, PHS provider institutions, etc.), pending implementation guidance and the results of
regulatory and reimbursement matters associated with our marketed products and product candidates.
Therefore, our estimates are subject to change. However, based on our current understanding of the
new healthcare reform law and assuming no significant changes in our current U.S. product sales
volume and mix, we currently estimate that the impact of the new healthcare reform law in 2011 will
be approximately two-and-a-half times the amount currently estimated for 2010. See discussion below
regarding the income statement classification of the costs associated
with the new healthcare reform law.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Accounting Treatment</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In accordance with GAAP, the increase in the amount of the Medicaid rebates and related
discounts that we will pay as a result of the changes imposed by the new healthcare reform law,
including as a result of extending such rebates and discounts to
additional healthcare providers, has
been and will continue to be reflected as a reduction of our product sales in our Condensed
Consolidated Statements of Income. The income statement presentation of the new fee on branded
prescription drugs to be paid by the manufacturers and importers beginning in 2011 has not yet been
determined by the U.S. accounting standards setting bodies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Prolia</I><SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> <I>Developments</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On May&nbsp;28, 2010, the European Commission (&#147;EC&#148;) granted marketing authorization for
Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> for the treatment of osteoporosis in postmenopausal women at increased risk
of fractures  and for the treatment of bone loss associated with hormone ablation in men with prostate
cancer at increased risk of fractures. The timing of reimbursement
authority approval of pricing in individual EU countries
will vary by country, which could follow the EC
approval by many months. For example, on July&nbsp;1, 2010, Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153; </SUP>received reimbursement
authority in Germany. We and GSK will jointly commercialize Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> for postmenopausal
osteoporosis (&#147;PMO&#148;) in Europe in accordance with a collaboration agreement entered into in July
2009.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On June&nbsp;1, 2010, the FDA approved Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> for the treatment of postmenopausal
women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture,
or multiple risk factors for fracture, or patients who have failed or are intolerant to other
available osteoporosis therapy. U.S. sales of Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> for the three months ended June
30, 2010 totaled approximately $3&nbsp;million, which was largely as a result of stocking of inventory
by wholesalers.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In consultation with the FDA, we have created several programs to help physicians and patients
make treatment decisions for postmenopausal women with osteoporosis at high risk for fracture and
to facilitate post-marketing safety surveillance. These include:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A REMS which communicates the product&#146;s risks. The Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> REMS consists
of a communication plan for healthcare providers and a medication guide for patients.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>A comprehensive post-marketing surveillance program. We will continue to gather data
from extension studies in more than 4,500 women with PMO who will have exposure to
Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> for up to 10&nbsp;years. In addition, we will implement an international
Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> long-term safety observational study to assess pre-specified AEs of
special interest based on seven existing data systems from five countries, which will
include healthcare administrative databases, electronic medical records, and national
health registries. These women with PMO who received Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> will be followed
long-term. Finally, we are launching the Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> Post marketing Active Safety
Surveillance Program to monitor the long-term safety of Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> and improve
the quality of data collected in the post-marketing setting. This program is intended to
enhance the AEs reporting system by soliciting reports of pre-specified AEs of special
interest.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Other Denosumab* Developments</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On May&nbsp;14, 2010, we submitted a Biologics License Application (&#147;BLA&#148;) to the FDA for denosumab
for the reduction of skeletal related events (&#147;SREs&#148;) in
cancer patients. Skeletal
metastases weaken and destroy bone. This can result
in a number of serious complications, collectively called SREs, comprising fracture, radiation to
bone, surgery to bone or spinal cord compression. All can be serious complications for advanced
cancer patients. The BLA submission summarizes clinical experience from nearly 6,900 patients
across 18 clinical studies, including approximately 5,700 patients with advanced cancer in the
three pivotal Phase 3 head-to-head trials versus Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (zoledronic acid). On July&nbsp;16,
2010, we announced that the FDA granted priority review designation to our denosumab BLA.
Consistent with priority review guidelines, the FDA will target an Agency action within six months
of the application submission date, resulting in a Prescription Drug User Fee Act (&#147;PDUFA&#148;) action
date of  November&nbsp;18, 2010.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On June&nbsp;5, 2010, we announced detailed results from a Phase 3, head-to-head trial which
compared the efficacy and safety of denosumab versus Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in 1,901 patients with
hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary
endpoints and demonstrated denosumab&#146;s superiority over Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in delaying or
preventing SREs. These statistically significant results were presented in an oral session on June
6, 2010 at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago (Late Breaking
Abstract Number #LBA4507).
In this study, denosumab was superior to Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in significantly delaying the time
to first on-study SRE (Hazard Ratio (&#147;HR&#148;) 0.82, 95% Confidence Interval (&#147;CI&#148;): 0.71, 0.95; P =
0.008) with a median time to first on-study SRE of 20.7&nbsp;months versus 17.1&nbsp;months for
Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. Denosumab was also superior to Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in significantly delaying the
development of multiple SREs (time to first and subsequent on-study SRE) (HR 0.82, 95% CI: 0.71,
0.94; P = 0.004).
Overall rates of AEs and serious AEs, including infections, were generally similar between the
two arms. Osteonecrosis of the jaw (&#147;ONJ&#148;) was infrequent (22 patients receiving denosumab (2.3%)
as compared with 12 patients receiving Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (1.3%)); the incidence of ONJ was not
significantly different between treatment arms. As with previous studies in advanced cancer
patients, hypocalcemia was more frequent in the denosumab arm. Both overall survival (&#147;OS&#148;) (HR
1.03, 95% CI: 0.91, 1.17; P=0.65) and the time to cancer progression (HR 1.06, 95% CI: 0.95, 1.18;
P=0.30) were balanced between treatment arms. The most common AEs for denosumab were anemia, back
pain, and nausea, and the most common AEs for Zometa<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> were anemia, back pain, and
decreased appetite. The data from this trial, which we had previously announced on February&nbsp;8,
2010, were included in our May&nbsp;14, 2010 BLA filed with the FDA.
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD><div align="justify">Denosumab has been
approved under the trade name
Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP>
in multiple regions to treat certain bone loss conditions. The trade
name of Denosumab may be different for advanced cancer indications
with higher dosing and/or more frequent administration.</div></TD>
</TR>

</TABLE>


<P align="center" style="font-size: 12pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>ESA Developments</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On February&nbsp;16, 2010, Amgen and Centocor Ortho Biotech Products, L.P. (&#147;Centocor Ortho Biotech
Products&#148;), a subsidiary of Johnson&nbsp;&#038; Johnson (&#147;J&#038;J&#148;), announced that the FDA approved a REMS for ESAs which includes
Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and Procrit<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (Epoetin alfa). As part of the
REMS, a medication guide explaining the risks of ESAs must be provided to all patients receiving
ESAs. In addition, the ESA APPRISE (Assisting Providers and cancer Patients with Risk Information
for the Safe use of ESAs) Oncology Program was established as a part of the ESA REMS. The FDA has
determined that a REMS is necessary for ESAs to ensure the benefits of these drugs outweigh the
risks of shortened OS and/or increased tumor progression or recurrence as identified in clinical
studies in patients with breast, non-small cell lung, head and neck, lymphoid and cervical cancers.
In order to ensure continued access to ESAs for healthcare providers who prescribe, or prescribe
and dispense, ESAs to patients with cancer, healthcare providers and
hospitals are required to train and enroll in the ESA
APPRISE Oncology Program by February&nbsp;15, 2011. Enrolled
prescribers are required to document that a discussion about the risks of
ESAs took place with each patient prior to the initiation of each new course of ESA therapy. The
ESA APPRISE Oncology Program was launched on March&nbsp;24, 2010. Direct patient registration or
approval prior to ESA administration is not required through the ESA APPRISE Oncology Program.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On March&nbsp;24, 2010, the Centers for Medicare &#038; Medicaid Services (&#147;CMS&#148;) held a Medicare
Evidence Development &#038; Coverage Advisory Committee (&#147;MEDCAC&#148;) meeting to examine the currently
available evidence on the use of ESAs to manage anemia in patients who have chronic kidney disease
(&#147;CKD&#148;). There was no clear outcome from the MEDCAC meeting. Additionally, on June&nbsp;16,
2010, the CMS opened a national coverage analysis (&#147;NCA&#148;) for the use of ESAs to manage anemia in
patients with CKD and dialysis-related anemia, which is generally the CMS&#146; first step toward
developing a national coverage determination (&#147;NCD&#148;). Generally, a NCD is a national policy
statement granting, limiting or excluding Medicare coverage or reimbursement for a specific medical
item or service. The CMS has stated that the NCA process for ESAs will conclude on or before June
16, 2011, but the CMS could propose a NCD at any time prior to that deadline. We also expect that
the discussions at the proposed FDA drug advisory committee meeting expected to be held later this
year may inform decisions about coverage and reimbursement policies for ESAs in patients with CKD.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On July&nbsp;26, 2010, the CMS released the Final Rule on Bundling in Dialysis which goes into
effect January&nbsp;2011. Key provisions under this rule include the following:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Unit of payment &#150; the CMS finalized its proposal to continue a per treatment unit of
payment. Consistent with current policy, end stage renal disease (&#147;ESRD&#148;) facilities
could be paid for up to three treatments per week, unless medical necessity justifies
more than three treatments per week.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Payment rate &#150; for 2011 the base rate is $229.63.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Oral drugs without intravenous equivalents &#150; oral-only drugs, such as Sensipar<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and
phosphate binders, will remain under Medicare beneficiaries&#146; prescription drug benefit
and paid for under Medicare Part&nbsp;D until 2014 when they will be reimbursed in the
bundle.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Under the final rule, ESRD facilities must elect, by November&nbsp;1, 2010, whether they will
implement the final rule in its entirety beginning in 2011. If they do not elect to do so, they
will implement the bundling provisions ratably over a four-year period beginning in 2011. Further,
in preparation of implementing the final rule, ESRD facilities may begin to transition their
treatment protocols in the second half of 2010, which could impact the dose/utilization of EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition, on July&nbsp;26, 2010, the CMS also published concurrently the ESRD Quality
Improvement Program (&#147;QIP&#148;) Proposed Rule. This proposed rule will have a 60&nbsp;day comment period
ending September&nbsp;24, 2010. Under the QIP, beginning in 2012, ESRD facilities will be subject to a
payment penalty of up to 2% of amounts reimbursed for failure to meet or exceed the CMS&#146; standards.
The CMS proposes that the penalty be based upon a composite score of measures as follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The percent of Medicare patients with hemoglobin (&#147;Hb&#148;) levels below 10 grams per
deciliter (&#147;g/dL&#148;) constitutes 50% of the weighting.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The percent of Medicare patients with Hb levels above 12 g/dL
represents 25% of the weighting.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The percent of Medicare patients with an average Urea Reduction Ratio of greater
than or equal to 65% constitutes 25% of the weighting.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Certain of these ESA developments may have material adverse impact on our business and results
of operations.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Vectibix</I><I><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (panitumumab)&nbsp;Developments </I></DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On April&nbsp;16, 2010, our application for marketing authorization for the use of
Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in the first and second line treatment of metastatic colorectal cancer
(&#147;mCRC&#148;) in patients whose tumors contain wild type KRAS genes was submitted to the European
Medicines Agency (&#147;EMA&#148;).
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">There are many factors that affect us and our industry in general, including, among others,
those relating to increased complexity and cost of R&#038;D due, in part, to greater scrutiny of
clinical trials with respect to safety which may lead to fewer treatments being approved by the FDA
or other regulatory bodies and/or safety-related label changes for approved products; increasing
restrictions on the use of our products; increasingly intense competition for marketed products and
product candidates, including biosimilars; reimbursement changes; healthcare provider prescribing
behavior; regulatory or private healthcare organization medical guidelines and reimbursement
practices; complex and expanding regulatory requirements and intellectual property protection.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Results of Operations</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Product sales</I>

</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Worldwide product sales were as follows (dollar amounts in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->


<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Three
months ended</B><BR><B>June 30,</B></TD>

    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Six
months ended</B><BR><B>June 30,</B></TD>


</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>


</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">603</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">693</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,319</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">638</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,174</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,158</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,353</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,231</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">5</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ENBREL</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">877</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,681</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Sensipar<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">172</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">167</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">351</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">315</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">11</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">29</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">139</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">109</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">28</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Nplate<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">104</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Prolia&#153;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,613</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,634</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">7,141</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">6,872</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Product sales are influenced by a number of factors, some of which may impact sales of
certain products more significantly than others, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>demand;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>wholesaler and end-user inventory management practices;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>contracting and pricing strategies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>recently enacted U.S. healthcare reform;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>third-party reimbursement availability and policies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>government programs;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>governmental or private organization regulations or guidelines relating to the use of
our product;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>clinical trial outcomes;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>AEs or results from clinical trials, including sub-analyses, studies or meta-analyses
performed by us or by others (including our licensees or independent investigators), which
could impact product safety labeling and may negatively impact healthcare provider
prescribing behavior, use of our products, regulatory or private healthcare organization
medical guidelines and reimbursement practices;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>clinical practice;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>patient population growth;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>new product launches and indications;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>competitive products;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fluctuations in foreign currency exchange rates;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the current global economic environment;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>product supply; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>acquisitions.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition, general economic conditions may affect, or in some cases amplify, certain of
these factors with a corresponding impact on our product sales.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Aranesp</I><SUP style="FONT-size: 85%; vertical-align: text-top"><I><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Total Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales by geographic region were as follows (dollar amounts in
millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->


<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>


<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Three
months ended</B><BR><B>June 30,</B></TD>

    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Six
months ended</B><BR><B>June 30,</B></TD>


</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>


</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">

<TD><DIV style="margin-left:15px; text-indent:-15px">Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; U.S.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">267</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">338</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(21</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">535</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">630</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(15</TD>
    <TD nowrap>)%</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; International</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">336</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">355</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(5</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">695</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">689</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">603</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">693</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(13</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,319</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(7</TD>
    <TD nowrap>)%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">U.S. Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the three and six months ended June&nbsp;30, 2010 decreased
21% and 15%, respectively. The decreases were driven by declines in demand due to decreases in
units sold reflecting an overall decline in the segment, and to a lesser extent, a slight loss of
segment share. The decline in U.S. Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the six months ended June&nbsp;30, 2010
was slightly offset by favorable changes in wholesaler inventories.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The 5% decrease in international Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the three months ended June&nbsp;30,
2010 was due to a decrease in demand reflecting an overall decline in the segment, partially offset
by a slight positive impact of foreign currency exchange rates of $3&nbsp;million. The 1% increase in
international Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the six months ended June&nbsp;30, 2010 is primarily due to
the positive impact of changes in foreign currency exchange rates, which aggregated
approximately $19&nbsp;million, partially offset by a decrease in demand. For the three and six months
ended June&nbsp;30, 2010, excluding the impact of foreign currency exchange rate changes, international
Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales decreased 6% and 2%, respectively.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition to other factors mentioned in the &#147;<I>Product sales</I>&#148; section above, future
Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales will be dependent, in part, on such factors as:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulatory developments, including:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the REMS for our ESAs, including the pace and extent of
enrollment by healthcare providers and hospitals in the ESA APPRISE Oncology
Program by February 15, 2011, and compliance with the requirement to document
discussions with each patient for each new course of therapy about
the risk of ESAs;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the ESA product label changes reflecting certain results of our Trial to Reduce
Cardiovascular Endpoints with Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Therapy (&#147;TREAT&#148;) study (&#147;TREAT label
changes&#148;);</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 12pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-alixgn:justify">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the proposed FDA advisory committee meeting in 2010 to re-evaluate the use of ESAs to
treat anemia in patients with CKD;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> future product label changes, including those we are currently discussing with regulatory authorities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reimbursement developments, including those resulting from:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the NCA, which the CMS opened in June&nbsp;2010, for the use of ESAs to manage anemia in
patients with CKD and dialysis-related anemia;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the results of the CMS&#146; MEDCAC meeting in March&nbsp;2010 to examine currently available
evidence on the use of ESAs to manage anemia in patients who have CKD;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> governments&#146; and/or third-party payers&#146; reaction to regulatory developments,
including the REMS for our ESAs, the TREAT label changes and future product label
changes;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> changes in reimbursement rates or changes in the basis for reimbursement, including
Medicare and Medicaid, by the federal, U.S. state and foreign governments;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> cost containment pressures by third-party payers, including governments and private
insurance plans;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our ability to maintain worldwide segment share and differentiate Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
from current and potential future competitive therapies or products, including J&#038;J&#146;s
Epoetin alfa product marketed in the United States and certain other locations outside of
the United States and other competitors&#146; products outside of the United States, including
biosimilar products that have been launched;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>development of new protocols, tests and/or treatments for cancer and/or new
chemotherapy treatments or alternatives to chemotherapy that may have reduced and may
continue to reduce the use of chemotherapy in some patients;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>addressable patient population; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>expansion into new international territories.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Certain of these factors could have a material adverse impact on future sales of
Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>EPOGEN</I><SUP style="FONT-size: 85%; vertical-align: text-top"><I><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Total EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales were as follows (dollar amounts in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->



<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Three
months ended</B><BR><B>June 30,</B></TD>

    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Six
months ended</B><BR><B>June 30,</B></TD>

<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>


</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; U.S.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">638</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the three months ended June&nbsp;30, 2010 increased 3% primarily due
to an increase in demand and favorable changes in wholesaler inventories. The increase in demand
was principally due to increased patient population growth, partially offset by a
decrease in dose utilization. EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the six months ended June&nbsp;30, 2010
increased 6% primarily due to an increase in demand and, to a lesser extent, favorable changes in
wholesaler inventories. The increase in demand is due to an increase in patient population growth
and dose utilization.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition to other factors mentioned in the &#147;<I>Product sales</I>&#148; section above, future
EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales will be dependent, in part, on such factors as:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reimbursement developments, including those resulting from:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the CMS&#146; Final Rule on Bundling in Dialysis,
including the extent to which ESRD facilities elect to fully adopt,
by November 1, 2010, the final rule in its entirety beginning in 2011
and the extent to which ESRD facilities begin to transition their
treatment protocols in the second half of 2010 in preparation for
implementing the final rule;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the NCA, which the CMS opened in June&nbsp;2010, for the use of ESAs to manage anemia in
patients with CKD and dialysis-related anemia;</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 12pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the results of the CMS&#146; MEDCAC meeting in March&nbsp;2010 to examine currently available
evidence on the use of ESAs to manage anemia in patients who have CKD;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the federal government&#146;s reaction to regulatory developments, including the REMS for
our ESAs, which we have recently implemented, and future product label changes;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> cost containment pressures from the federal and state governments on healthcare
providers;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> other changes in reimbursement rates or changes in the basis for reimbursement by the
federal and state governments, including Medicare and Medicaid;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulatory developments, including those resulting from:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the REMS for our ESAs;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> the proposed FDA advisory committee meeting in 2010 to re-evaluate the use of ESAs to
treat anemia in patients with CKD;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="11%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left">&#150;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> future product label changes;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in dose fluctuations as healthcare providers continue to refine their treatment
practices to maintain patient Hb levels in the 10 to 12 g/dL range;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>governmental or private organization regulations or guidelines relating to the use of
our products, including changes in medical guidelines and legislative actions;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in dose utilization or route of administration; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>development of new modalities or therapies to treat anemia associated with CRF.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Certain of these factors could have a material adverse impact on future sales of
EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Neulasta</I><SUP style="FONT-size: 85%; vertical-align: text-top"><I><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>/NEUPOGEN</I><SUP style="FONT-size: 85%; vertical-align: text-top"><I><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Total Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales by geographic region were as follows
(dollar amounts in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->


<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Three
months ended</B><BR><B>June 30,</B></TD>

    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Six
months ended</B><BR><B>June 30,</B></TD>

<TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>


</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">

<TD><DIV style="margin-left:15px; text-indent:-15px">Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; U.S.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">643</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">625</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,219</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">5</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; U.S.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">225</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">450</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">432</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">U.S. Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">868</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">855</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,730</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,651</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">5</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; International</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">218</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">206</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">6</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">444</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">389</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">14</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; International</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(9</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">179</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">191</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(6</TD>
    <TD nowrap>)%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">International Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> &#151; Total</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">306</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">303</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">623</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">580</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,174</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,158</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,353</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,231</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">5</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">U.S. sales of Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> for the three months ended June
30, 2010 increased 2% due primarily to favorable changes in wholesaler inventories, partially
offset by a low single-digit percentage point decrease in demand. The decrease in demand was driven
by a decline in units sold, partially offset by a mid single-digit percentage point increase in the
average net sales price. U.S. sales of Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> for the six months
ended June&nbsp;30, 2010 increased 5% due to favorable changes in wholesaler inventories and, to a
lesser extent, an increase in demand. The increase in demand was driven by a mid single-digit
percentage point increase in the average net sales price, partially offset by a decline in units
sold.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">International Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the three months ended June
30, 2010 increased 1% primarily driven by the positive impact of changes in foreign currency
exchange rates of $5&nbsp;million. This increase was partially offset by a slight decrease in demand.
International Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales for the six months ended June&nbsp;30,
2010 increased 7% due to an increase in demand and the positive impact of changes in foreign
currency exchange rates of $21&nbsp;million. The increase in demand was driven by expansion into newer
territories and the continued conversion from NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> to Neulasta. For the three and
six months ended
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:0%">June&nbsp;30, 2010, excluding the impact of foreign currency exchange rate changes,
international Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales decreased 1% and increased 4%,
respectively.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition to other factors mentioned in the &#147;<I>Product sales</I>&#148; section above, future
Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales will be dependent, in part, on such factors as:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in reimbursement rates or changes in the basis for reimbursement, including
Medicare and Medicaid, by the federal, U.S. state and foreign governments;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>development of new protocols, tests and/or treatments for cancer and/or new
chemotherapy treatments or alternatives to chemotherapy that may have reduced and may
continue to reduce the use of chemotherapy in some patients;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>expansion into new international territories;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>competitive products, including biosimilar products that have been or may be approved
and launched in the EU;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the availability, extent and access to reimbursement from government and third-party
payers;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost containment pressures from governments and private insurers on healthcare
providers; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>penetration of existing segments.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Certain of these factors could have a material adverse impact on future sales of
Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>ENBREL</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Total ENBREL sales by geographic region were as follows (dollar amounts in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->


<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>


<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Three
months ended</B><BR><B>June 30,</B></TD>

    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Six
months ended</B><BR><B>June 30,</B></TD>


</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ENBREL &#151; U.S.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">819</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">846</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,573</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,558</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ENBREL &#151; Canada</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">53</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">9</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">99</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">9</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total ENBREL</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">877</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,681</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The 2% decline in ENBREL sales for the three months ended June&nbsp;30, 2010 was driven by a
decrease in demand. The decrease in demand was principally due to a mid single-digit percentage
point decline in units sold, reflecting a share decline primarily as a result of increased
competitive activity in dermatology, partially offset by an increase in the average net sales
price. The 1% increase in ENBREL sales for the six months ended June&nbsp;30, 2010 was due to favorable
changes in wholesaler inventories. Demand for the six months ended June&nbsp;30, 2010 was relatively
unchanged as the low single-digit percentage point decline in units sold was substantially offset
by an increase in the average net sales price. ENBREL continues to maintain a leading position in
both the rheumatology and dermatology segments.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition to other factors mentioned in the &#147;<I>Product sales</I>&#148; section above, future ENBREL
sales will be dependent, in part, on such factors as:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the effects of competing products or therapies, including new competitive products,
such as Centocor Ortho Biotech&#146;s Simponi<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> (golimumab)&nbsp;and Stelara<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP>
(ustekinumab)&nbsp;and UCB/Nektar Therapeutics&#146; Cimzia<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (PEGylated anti-TNF alpha)
and, in part, our ability to differentiate ENBREL based on a combination of its safety
profile and efficacy;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in reimbursement rates or changes in the basis for reimbursement, including
Medicare and Medicaid, by the federal government and U.S. states;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the availability, extent and access to reimbursement from government and third-party
payers;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>future product label changes;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>risk management activities, including the recent modification to our REMS, undertaken
by us or required by the FDA or other regulatory authorities;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>growth in the rheumatology and dermatology segments; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>cost containment pressures from governments and private insurers on healthcare
providers.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 12pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Certain of these factors could have a material adverse impact on future sales of ENBREL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Selected operating expenses</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The following table summarizes selected operating expenses (dollar amounts in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->


<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Three
months ended</B><BR><B>June 30,</B></TD>

    <TD>&nbsp;</TD>

<TD nowrap align="center" colspan="11" style="border-bottom: 1px solid #000000"><B>Six
months ended</B><BR><B>June 30,</B></TD>


</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>

    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000"><B>Change</B></TD>
<TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cost of sales (excludes amortization of
certain acquired intangible assets)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">531</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">4</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">5</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">% of product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">15.3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">14.6</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">14.9</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">14.7</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">675</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">693</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3</TD>
    <TD nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,321</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,326</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">% of product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">18.7</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">19.1</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">18.5</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">19.3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">986</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">910</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">8</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,870</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,708</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">9</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:60px; text-indent:-15px">% of product sales</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">27.3</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">25.0</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">26.2</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">24.9</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>

</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Amortization of certain acquired
intangible assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0</TD>
    <TD nowrap>&nbsp;%</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">147</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">147</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">0</TD>
    <TD nowrap>&nbsp;%</TD>

</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other charges</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>

</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Cost of sales</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Cost of sales, which excludes the amortization of certain acquired intangible assets,
increased to 15.3% of product sales for the second quarter of 2010, primarily driven by higher bulk
material cost and less favorable product mix compared to the second quarter of 2009, partially
offset by lower royalties and excess capacity charges. Cost of sales increased to 14.9% of product
sales for the six months ended June&nbsp;30, 2010, primarily driven by higher bulk material cost,
partially offset by lower royalties compared to the six months ended June&nbsp;30, 2009.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Research and development</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">R&#038;D costs are expensed as incurred and primarily include salaries, benefits and other
staff-related costs; facilities and overhead costs; clinical trial and related clinical
manufacturing costs; contract services and other outside costs; R&#038;D information systems&#146; costs; and
amortization of acquired technology used in R&#038;D with alternative future uses. R&#038;D expenses include
costs incurred under R&#038;D arrangements with our corporate partners and costs and cost recoveries
associated with collaborative R&#038;D and in-licensing arrangements, including upfront fees and
milestones paid to collaboration partners in connection with technologies that have no alternative
future use. Net payment or reimbursement of R&#038;D costs for R&#038;D collaborations is recognized when the
obligation is incurred or as we become entitled to the cost recovery.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">R&#038;D expenses decreased 3% for the three months ended June&nbsp;30, 2010, which was primarily
attributable to lower milestone payments related to the $50&nbsp;million expense in the three months
ended June&nbsp;30, 2009 resulting from the payment to obtain an exclusive license to Cytokinetics
Incorporated&#146;s (&#147;Cytokinetics&#148;) cardiac contractility program, partially offset by lower expense
recoveries associated with ongoing collaborations of $33&nbsp;million and higher staff related costs of
$18&nbsp;million.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">R&#038;D
expenses remained essentially unchanged for the six months ended June&nbsp;30, 2010 compared to the
corresponding period of the prior year as the reduction related to the above-noted prior year $50
million payment to Cytokinetics and the current year lower denosumab SRE clinical trial costs of
$57&nbsp;million were offset by lower expense recoveries of $61&nbsp;million associated with our ongoing
collaborations and higher staff-related costs of $49&nbsp;million.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Selling, general and administrative</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Selling, general and administrative (&#147;SG&#038;A&#148;) expenses are primarily comprised of salaries,
benefits and other staff-related costs associated with sales and marketing, finance, legal and
other administrative personnel; facilities and overhead costs; outside marketing, advertising and
legal expenses and other general and administrative costs. SG&#038;A expenses include costs and cost
recoveries associated with certain collaborative arrangements. Net payment or reimbursement of SG&#038;A
costs for collaborations is recognized when the obligation is incurred or as we become entitled
to the cost recovery.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For the three months ended June&nbsp;30, 2010, the 8% increase in SG&#038;A expenses was primarily due
to increased spending for activities in anticipation of the approval and launch of
Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> and promotional costs on marketed products of $44&nbsp;million, higher litigation
expenses of $24&nbsp;million and higher staff-related costs of $14&nbsp;million. The increase in SG&#038;A
expenses was partially offset by expense recoveries of $10&nbsp;million related to our GSK collaboration
for Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> and lower expenses associated with the Pfizer profit share of $7&nbsp;million due
to lower ENBREL sales.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For the six months ended June&nbsp;30, 2010, the 9% increase in SG&#038;A expenses was primarily due to
increased spending for activities in anticipation of the approval and launch of Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP>
and promotional costs on marketed products of $89&nbsp;million, higher staff-related costs of $44
million, higher litigation expenses of $33&nbsp;million and higher expenses associated with the Pfizer
profit share of $14&nbsp;million due to higher ENBREL sales. The increase in SG&#038;A expenses was
partially offset by expense recoveries of $22&nbsp;million related to our GSK collaboration for
Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">&#153;</SUP> and $17&nbsp;million of charges for certain cost savings initiatives in 2009 related
to our 2007 restructuring plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Interest expense, net</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For the three months ended June&nbsp;30, 2010 and 2009, interest expense, net was $147&nbsp;million and
$150&nbsp;million, respectively. Included in interest expense, net for the three months ended June&nbsp;30,
2010 and 2009, is the impact of non-cash interest expense of $66&nbsp;million and $62&nbsp;million,
respectively, resulting from the change in the accounting for our convertible debt effective
January&nbsp;1, 2009.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For the six months ended June&nbsp;30, 2010 and 2009, interest expense, net was $292&nbsp;million and
$297&nbsp;million, respectively. Included in interest expense, net for the six months ended June&nbsp;30,
2010 and 2009, is the impact of non-cash interest expense of $131&nbsp;million and $123&nbsp;million,
respectively, resulting from the change in the accounting for our convertible debt effective
January&nbsp;1, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Interest and other income, net</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For the three months ended June&nbsp;30, 2010 and 2009, interest and other income, net was $94
million and $50&nbsp;million, respectively. The increase for the three months ended June&nbsp;30, 2010 is
primarily due to higher net realized gains on investments of $23&nbsp;million and higher interest income
of $14&nbsp;million primarily due to a higher average cash, cash equivalents and marketable securities
balance.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For the six months ended June&nbsp;30, 2010 and 2009, interest and other income, net was $178
million and $108&nbsp;million, respectively. The increase for the six months ended June&nbsp;30, 2010 is
primarily due to higher net realized gains on investments of $43&nbsp;million, higher interest income of
$26&nbsp;million primarily due to a higher average cash, cash equivalents and marketable securities
 balance and higher foreign currency exchange net gains of $10&nbsp;million, partially offset by
higher losses of $12&nbsp;million on certain leased facilities that will no longer be used in our
operations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Income taxes</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Our effective tax rate for the three and six months ended June&nbsp;30, 2010 was 17.9% compared to
6.5% and 11.6%, respectively, for the same periods last year. The increases in our effective tax
rates were primarily due to: (i)&nbsp;favorable resolution of certain prior years&#146; non-routine transfer
pricing matters with the IRS during the three months ended June&nbsp;30, 2009, (ii)&nbsp;a benefit in the
three months ended March&nbsp;31, 2009 relating to adjustments to previously established deferred taxes
due to changes in California tax law effective for future periods; (iii)&nbsp;the exclusion of the
benefit of the federal research and experimentation (&#147;R&#038;E&#148;) tax credit in the three and six months
ended June&nbsp;30, 2010 (the federal R&#038;E credit expired as of December&nbsp;31, 2009 and was not reinstated
as of June&nbsp;30, 2010); partially offset by (iv)&nbsp;increased manufacturing and profits in Puerto Rico,
which are taxed under an incentive grant, and changes in revenue and expense mix. The resolution of
prior years&#146; tax matters recognized in the three months ended June&nbsp;30, 2009 reduced the effective
tax rates for the three and six months ended June&nbsp;30, 2009 by 8.5% and 4.4%, respectively.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">See Note 2, &#147;<I>Income taxes</I>&#148; to the Condensed Consolidated Financial Statements for further
discussion.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Financial Condition, Liquidity and Capital Resources</B>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The following table summarizes selected financial data (in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash, cash equivalents and marketable securities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">14,523</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">13,442</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39,629</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Current debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,414</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Non-current debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9,318</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,601</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,170</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22,667</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We believe that existing funds, cash generated from operations and existing sources of
and access to financing are adequate to satisfy our working capital, capital expenditure and debt
service requirements for the foreseeable future including the repayment of our 2011 Convertible
Notes with a principal balance of $2.5&nbsp;billion due in February&nbsp;2011. In addition, we plan to
opportunistically pursue our stock repurchase program and other business initiatives, including
acquisitions and licensing activities. We anticipate that our liquidity needs can be met through a
variety of sources, including cash provided by operating activities, sale of marketable
securities, borrowings through commercial paper and/or our syndicated credit facility and access to
other debt markets and equity markets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Cash, cash equivalents and marketable securities</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Of the total cash, cash equivalents and marketable securities at June&nbsp;30, 2010, approximately
$12.3&nbsp;billion was generated from operations in foreign tax jurisdictions and is held outside the
U.S. and is intended for use in our foreign operations. If these funds were repatriated for use in
our U.S. operations, we would be required to pay additional U.S. federal and state income taxes at
the applicable marginal tax rates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Financing arrangements</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The following table identifies our borrowings under our various financing arrangements (in
millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>June 30,</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>December 31,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2011 Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,414</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,342</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2013 Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,088</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2017 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,099</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,099</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2014 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,000</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2019 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">998</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2039 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">996</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">995</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2037 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">899</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">899</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2040 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">696</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2018 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2038 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">499</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2020 Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">2032 Modified Convertible Notes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total borrowings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,732</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,601</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Less current portion (2011 Convertible Notes)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,414</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total non-current debt</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">9,318</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">10,601</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Certain of our financing arrangements contain non-financial covenants and we were in
compliance with all applicable covenants as of June&nbsp;30, 2010. None of our financing arrangements
contain any financial covenants.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">See Note 6, &#147;<I>Financing arrangements</I>&#148; to the Condensed Consolidated Financial Statements for
further discussions of our long-term borrowings.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><I>Cash flows</I>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The following table summarizes our cash flow activity (in millions):
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="71%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Six months ended June 30,</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2010</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>2009</B></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash provided by operating activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,477</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,538</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash used in investing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(2,390</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,442</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net cash (used in) provided by financing activities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,259</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Operating</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Cash provided by operating activities has been and is expected to continue to be our primary
recurring source of funds. Cash provided by operating activities during the six months ended June
30, 2010 decreased primarily due to the timing and amounts of payments to taxing authorities and
the timing and receipt of payments from certain corporate partners, partially offset by higher net
income, the timing of payments to vendors and a reduction in inventory.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Investing</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">During the six months ended June&nbsp;30, 2010 and 2009 cash was used for investing activities
primarily due to the net purchases of marketable securities. Net purchases of marketable securities
were $2.1&nbsp;billion for the six months ended June&nbsp;30, 2010 compared to net purchases of $1.2&nbsp;billion
for the six months ended June&nbsp;30, 2009. Capital expenditures totaled $271&nbsp;million during the six
months ended June&nbsp;30, 2010 compared to $256&nbsp;million during the corresponding period of the prior
year. The capital expenditures during the six months ended June&nbsp;30, 2010 and 2009 were primarily
associated with manufacturing capacity expansions in Puerto Rico and other site development. We
currently estimate 2010 spending on capital projects and equipment to be approximately $600
million.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Financing</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In March&nbsp;2010, we issued $700&nbsp;million aggregate principal amount of notes due in 2040 (the
&#147;2040 Notes&#148;) and $300&nbsp;million aggregate principal amount of notes due in 2020 (the &#147;2020 Notes&#148;)
in a registered offering. The 2040 Notes and 2020 Notes pay interest at fixed annual rates of 5.75%
and 4.50%, respectively. The 2040 Notes and 2020 Notes may be redeemed at any time at our option,
in whole or in part, at 100% of the principal amount of the notes being redeemed plus accrued and
unpaid interest, if any, and a &#147;make-whole&#148; amount, as defined. Upon the occurrence of a change in
control triggering event, as defined, we may be required to purchase for cash all or a portion of
the 2040 Notes and the 2020 Notes at a price equal to 101% of the principal amount of the notes
plus accrued interest. Debt issuance costs incurred in connection with the issuance of this debt totaled approximately $7&nbsp;million and are being amortized
over the lives of the notes.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">During
the six months ended June&nbsp;30, 2010, we repurchased 39.4&nbsp;million shares of our common
stock at a total cost of $2.3&nbsp;billion. During the six months ended June&nbsp;30, 2009, we repurchased
37.5&nbsp;million shares of our common stock at a total cost of $2.0&nbsp;billion. As of June&nbsp;30, 2010, we
had $3.7&nbsp;billion available for stock repurchases as authorized by our Board of Directors.
Repurchases under our stock repurchase program reflects, in part, our confidence in the long-term
value of our common stock. Additionally, we believe that it is an effective way of returning cash
to our stockholders. The manner of purchases, amount we spend and the number of shares repurchased
will vary based on a number of factors including the stock price, blackout periods in which we are
restricted from repurchasing shares, and our credit rating and may include private block purchases
as well as market transactions.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We receive cash from the exercise of employee stock options and proceeds from the sale of
stock under our employee stock purchase program. Our equity award
programs provided $54&nbsp;million and $97&nbsp;million of cash during the six
months ended June&nbsp;30, 2010 and 2009, respectively. Proceeds from the exercise of employee stock
options will vary from period to period based upon, among other factors, fluctuations in the market
value of our stock relative to the exercise price of such options.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;4.</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>CONTROLS AND PROCEDURES</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We maintain &#147;disclosure controls and procedures,&#148; as such term is defined under Exchange Act
Rule&nbsp;13a-15(e), that are designed to ensure that information required to be disclosed in Amgen&#146;s
Exchange Act reports is recorded, processed, summarized and reported within the time periods
specified in the SEC&#146;s rules and forms, and that such information is accumulated and communicated
to Amgen&#146;s management, including its Chief Executive Officer and Chief Financial Officer, as
appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating
the disclosure controls and procedures, Amgen&#146;s management recognized that any controls and
procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives and, in reaching a reasonable level of assurance, Amgen&#146;s
management necessarily was required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. We have carried out an evaluation under the
supervision and with the participation of our management, including Amgen&#146;s Chief Executive Officer
and Chief Financial Officer, of the effectiveness of the design and operation of Amgen&#146;s disclosure
controls and procedures. Based upon their evaluation and subject to the foregoing, the Chief
Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures
were effective as of June&nbsp;30, 2010.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Management determined that, as of June&nbsp;30, 2010, there were no changes in our internal control
over financial reporting that occurred during the fiscal quarter then ended that have materially
affected, or are reasonably likely to materially affect, our internal control over financial
reporting.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="109"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PART II &#151; OTHER INFORMATION</B>
</DIV>

<DIV align="left">
<A name="110"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>LEGAL PROCEEDINGS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">See Note 10, &#147;<I>Contingencies and commitments</I>&#148; to the condensed consolidated financial
statements included in our Form&nbsp;10-Q for the periods ended
June&nbsp;30, 2010 and March&nbsp;31, 2010 for discussions which are limited to certain recent developments concerning our legal
proceedings. These discussions should be read in conjunction with Note 20, &#147;<I>Contingencies and
commitments</I>&#148; to our consolidated financial statements in Part&nbsp;IV of our Annual Report on Form 10-K
for the year ended December&nbsp;31, 2009.
</DIV>
<DIV align="left">
<A name="111"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;1A.&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>RISK FACTORS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">This report and other documents we file with the SEC contain forward looking statements that
are based on current expectations, estimates, forecasts and projections about us, our future
performance, our business or others on our behalf, our beliefs and our management&#146;s assumptions.
These statements are not guarantees of future performance and involve certain risks, uncertainties
and assumptions that are difficult to predict. You should carefully consider the risks and
uncertainties facing our business. The risks described below are not the only ones facing us. Our
business is also subject to the risks that affect many other companies, such as employment
relations, general economic conditions, geopolitical events and international operations. Further,
additional risks not currently known to us or that we currently believe are immaterial also may
impair our business, operations, liquidity and stock price materially and adversely. There have
been no material changes from the risk factors disclosed in Part&nbsp;I, Item&nbsp;1A, of our Annual Report
on Form 10-K for the fiscal year ended December&nbsp;31, 2009, except
for those noted in Part&nbsp;II, Item&nbsp;1A. Risk Factors in our  Form&nbsp;10-Q for the period ended
March&nbsp;31, 2010 and below:
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Our current products and products in development cannot be sold if we do not gain or maintain
regulatory approval.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Our business is subject to extensive regulation by numerous state and federal governmental
authorities in the United States, including the FDA, and by foreign regulatory authorities,
including the EMA. We are required in the United States and in foreign countries to obtain approval
from regulatory authorities before we can manufacture, market and sell our products. Once approved,
the FDA and other U.S. and foreign regulatory agencies have substantial authority to require
additional testing, change product labeling or mandate withdrawals of our products. Also,
regulatory agencies could add new regulations or change existing regulations at any time, which
could affect our ability to obtain or maintain approval of our products. Regulatory reform efforts
currently under discussion by U.S. policymakers may include changes to applicable laws and
regulations that could have a significant impact on our business. For example, the 2007 creation of
the Food and Drug Administration Amendments Act of 2007 (&#147;FDAAA&#148;) significantly added to the FDA&#146;s
authority, allowing the FDA to (i)&nbsp;require sponsors of marketed products to conduct post-approval
clinical studies; (ii)&nbsp;mandate labeling changes to products and (iii)&nbsp;require sponsors to implement
a REMS for a product. Failure to comply with FDAAA requirements could result in significant civil
monetary penalties, reputational harm and increased product liability risk. We are unable to
predict when and whether any changes to regulatory policy affecting our business could occur, and
such changes could have a material adverse impact on our business.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Obtaining and maintaining regulatory approval has been and will continue to be increasingly
difficult, time-consuming and costly. For example, in October&nbsp;2009 we received Complete Response
Letters from the FDA for the BLA for  Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> in the
treatment and prevention of PMO and in the treatment and prevention of bone loss due to hormone
ablation therapy (&#147;HALT&#148;) in breast and prostate cancer patients. The Complete Response Letter
related to the PMO indication requested several items, including further information on the design
and background adverse event rates that will inform the methodology of our previously submitted
post-marketing surveillance program. The FDA also requested a new clinical program to support
approval of Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> for the prevention of PMO, updated safety data and stated that a
REMS is necessary for Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>. The Complete Response Letter related to the HALT
indication requested additional information regarding the safety of Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> in patients
with breast cancer receiving aromatase inhibitor therapy and patients with prostate cancer
receiving Androgen Deprivation Therapy (&#147;ADT&#148;). The FDA specifically requested results from
additional adequate and well-controlled clinical trials demonstrating that Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> has
no detrimental effects on either time to disease progression or OS.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition, there may be situations in which demonstrating the efficacy and safety of a
product candidate may not be sufficient to gain regulatory approval unless superiority to
comparative products can be shown. Further some of our products are approved by U.S. and foreign
regulatory authorities on a conditional basis with full approval conditioned upon fulfilling
requirements of regulators. Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, for example, received conditional approval in the
United States and EU, with final approval conditioned on conducting additional clinical trials of
the use of Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> as a therapy in treating mCRC. Our conditional approval of
Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in the EU was received in December&nbsp;2007 and is reviewed annually by the CHMP
and in December&nbsp;2008 and 2009 we received renewal of the conditional approval subject to us
completing an additional clinical trial in the existing approved indication. In 2009, the CHMP
approved our protocol for this additional clinical trial, which will compare the effect of
Vectibix<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> versus Erbitux<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> on OS for chemorefractory mCRC patients with
wild-type <I>KRAS </I>tumors. Further, some of our products or product candidates may be used with a
companion diagnostic product, such as a test-kit, or companion device, such as an injector or other
delivery system. These product candidates or expanded indications of our products may not be
approved if the companion diagnostic product or companion device
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>



<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">does not gain or maintain regulatory approval. These companion diagnostics and devices may be
provided by single-source unaffiliated third-party companies. We are dependent on the sustained
cooperation and effort of these third-party companies in conducting the studies required for such
approval by the applicable regulatory agencies. Delays in the studies or failure of the third-party
company to obtain regulatory approval of the companion diagnostic or device could negatively impact
the approval of our product candidate or the expanded indication of our product and we may incur
increased development costs, delays in regulatory approval, associated delays in a product
candidate reaching the market or the expansion of existing product labels for new indications.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The occurrence of a number of high profile safety events has caused an increased public and
governmental concern about potential safety issues relating to pharmaceutical and biological
products and certain of our products and product candidates. (See &#151; <I>&#147;Our ESA products continue to
be under review and receive scrutiny by regulatory authorities.&#148;</I>) As a result of this increased
concern in recent years, the U.S. regulatory environment has evolved and safety signals and safety
concerns resulting from clinical trials (including sub-analyses and meta-analyses), market use or
other sources are receiving greater scrutiny. Actual or perceived safety problems could lead to
revised or restrictive labeling of our approved products or a class of products, potentially
including limitations on the use of approved products in certain patients because of:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the identification of actual or theoretical safety or efficacy concerns with respect to
any of our products by regulatory agencies</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>an increased rate or number of previously-identified safety-related events</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the discovery of significant problems or safety signals or trends with a similar
product that implicates an entire class of products</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>subsequent concerns about the sufficiency of the data or studies underlying the label
or changes to the underlying safety/efficacy analysis related to results from clinical
trials, including sub-analyses, or meta-analysis (a meta-analysis is the review of studies
using various statistical methods to combine results from previous separate but related
studies) of clinical trials or clinical data performed by us or others</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>new legislation or rules by regulatory agencies</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For example, on December&nbsp;16, 2009, based on the TREAT results, we updated the boxed warning in
the labeling information for ESAs, to reflect an increased risk of stroke when ESAs are
administered to CRF patients to target Hb levels of 13 g/dL and
above. (See&#151;<I>&#147;Our ESA products
continue to be under review and receive scrutiny by regulatory authorities.&#148;</I>)
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition to revised labeling for our products, discovery of new safety information or
previously unknown safety concerns and/or safety signals with our products could also lead to:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>requirement of risk management activities (including a REMS) or other FDA compliance
actions related to the promotion and sale of our products</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>mandated PMCs or pharmacovigilance programs for our approved products</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>product recalls of certain of our approved products</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>revocation of approval for our products from the market completely, or within
particular therapeutic areas, and/or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>increased timelines or delays in being approved by the FDA or other regulatory bodies</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>fewer treatments or product candidates being approved by regulatory bodies</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Product safety concerns could cause regulatory agencies to impose risk management activities
upon us (including a REMS), which may require substantial costs and resources to negotiate, develop
and implement. The results of these risk management activities could:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>impact the ability of healthcare providers to prescribe, dispense or use our products</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>limit patient access to our products</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>place administrative burdens on healthcare providers in prescribing our products, or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>affect our ability to compete against products that do not have a REMS or similar risk
management activities</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We currently have approved REMS for our ESAs, ENBREL, Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and
Nplate<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and we use third-party service providers to assist in the administration of our
REMS that include elements to assure safe use. If we or third-party service providers acting
on our behalf fail to effectively implement and/or administer the REMS for our products, we may be
required to modify such REMS and we may be subject to FDA enforcement actions or to civil
penalties.

</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Further, if new medical data or product quality issues suggest an unacceptable safety risk or
previously unidentified side-effects, we may withdraw some or all affected product&#151;either
voluntarily or by regulatory mandate&#151;in certain therapeutic areas, or
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">completely recall a product presentation from the market for some period or permanently. For
example, in September&nbsp;2009, we initiated a voluntary recall of a limited number of ENBREL
SureClick<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> lots due to a defect in the glass syringe barrel which resulted in a small
number of broken syringes following assembly of the autoinjector device. We may experience the same
or other problems in the future resulting in broader product recalls or adverse event trends, which
may adversely affect the sales of our products. Additionally, if other parties (including our
licensees, such as J&#038;J and Pfizer, or independent investigators) report or fail to effectively
report to regulatory agencies side effects or other safety concerns that occur from their use of
our products in clinical trials or studies or from marketed use, resulting regulatory action could
adversely affect the sales of our products and our business and results of operations.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">If regulatory authorities determine that we have not complied with regulations in the R&#038;D of a
product candidate, a new indication for an existing product or information to support a current
indication, they may not approve the product candidate or new indication or maintain approval of
the current indication in its current form or at all, and we would not be able to market and sell
it. If we were unable to market and sell our products or product candidates, our business and
results of operations would be materially and adversely affected. Further, safety signals, trends,
AEs or results from clinical trials or studies performed by us or by others (including our
licensees or independent investigators) from the marketed use of our drugs that result in revised
safety-related labeling or restrictions on the use of our approved products could negatively impact
healthcare provider prescribing behavior, use of our products, regulatory or private health
organization medical guidelines and reimbursement for our products all of which would have a
material adverse effect on our business and results of operations.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Our ESA products continue to be under review and receive scrutiny by regulatory authorities.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Beginning in 2006, adverse safety results involving ESA products were observed and since that
time our ESAs have been the subject of ongoing review and scrutiny from regulatory authorities. In
the United States, the FDA continues to review the benefit-risk profile of ESAs, which have
resulted and could result in future changes to ESA labeling and usage. For example, we revised the
labeling for our ESAs in August&nbsp;2008, as the FDA directed, and since that time have experienced a
reduction in our ESA sales, in particular Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales in the U.S. supportive cancer
care setting. In October&nbsp;2009, the results from TREAT, a phase 3 pivotal study of patients with CKD
not on dialysis were published in the <I>New England Journal of Medicine</I>. The study failed to meet its
primary objectives of demonstrating a reduction in all-cause mortality, cardiovascular morbidity,
including heart failure, heart attack, stroke or hospitalization for myocardial ischemia, or time
to ESRD. On December&nbsp;16, 2009, based on the TREAT results, we updated the boxed warning in the
labeling information for ESAs, to reflect an increased risk of stroke when ESAs are administered to
CRF patients to target Hb levels of 13 g/dL and above. In an editorial published in the <I>New England
Journal of Medicine </I>in January&nbsp;2010, the FDA announced that it will call an advisory committee
meeting in 2010 to re-evaluate the use of ESAs to treat anemia in patients with CKD and could
consider lowering targeted Hb levels. In addition, CMS held a MEDCAC meeting on March&nbsp;24, 2010 to
examine currently available evidence on the use of ESAs to manage anemia in patients who have CKD,
which considered the results from the TREAT study, and on June&nbsp;16, 2010, CMS opened a NCA for the
use of ESAs to manage anemia in patients with CKD and dialysis-related anemia. (See &#151; <I>&#147;Our sales
depend on coverage and reimbursement from third-party payers.&#148;</I>) Although we cannot predict what
impact all of these activities could have on our business, the revised ESA labeling or any future
labeling changes, including any required in connection with the scheduled advisory committee
meeting, our ongoing discussions with the FDA regarding the conversion of the format of our ESA
U.S. labels in accordance with the Physician&#146;s Labeling Rule or other changes required by the FDA,
the outcome from the NCA or the impact of the approved REMS for ESAs could have a material adverse
impact on the coverage, reimbursement and sales of our ESAs, which would have a material adverse
effect on our business and results of operations. (See &#151; <I>&#147;Our current products and products in
development cannot be sold if we do not gain or maintain regulatory approval.&#148;</I>)
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We also have ongoing PMCs for our ESAs which must be conducted to maintain regulatory approval
and marketing authorization. We have agreed with the FDA to a robust pharmacovigilance program to
continue to study the safety surrounding the use of ESAs in the oncology setting and we initiated
Study 782 as part of our Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> pharmacovigilance program, a phase 3 non-inferiority
study evaluating OS when comparing non-small cell lung cancer patients on Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> to
patients receiving placebo. We are currently identifying clinical sites for Study 782 and have
begun enrolling patients in the study. Further, in 2008 the FDA and EMA reviewed interim results
from the Preoperative Epirubicin Paclitaxel Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> (&#147;PREPARE&#148;) study in neo-adjuvant
breast cancer, a PMC study, which were ultimately incorporated into the ESA labeling in both the
United States and the EU. We received the final results from the PREPARE study in 2009, which were
substantially consistent with the interim results, and provided that data to the FDA and EMA.
Although we cannot predict the results or the outcomes of ongoing clinical trials, or the extent to
which regulatory authorities may require additional labeling changes as a result of these or other
trials, we cannot exclude the possibility that adverse results from clinical trials, including
PMCs, could have a material adverse impact on the reimbursement, use and sales of our ESAs, which
would have a material adverse effect on our business and results of operations.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Regulatory authorities outside the United States have also reviewed and scrutinized the use of
our ESA products. In June&nbsp;2008, the EMA recommended updating the product information for ESAs with
a new warning for their use in cancer patients, which was approved by the EC in October&nbsp;2008. The
product information for all ESAs was updated to advise that in some clinical situations
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">blood transfusions should be the preferred treatment for the management of anemia in patients
with cancer and that the decision to administer ESAs should be based on a benefit-risk assessment
with the participation of the individual patient. Since the October&nbsp;2008 revision, we have
experienced a reduction of Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> sales in the supportive cancer care setting in the
EU and, although we cannot predict what further impact the revised EU ESA product information could
have on our business, the reimbursement, use and sales of Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in Europe could
further be materially adversely affected, which would have a material adverse effect on our
business and results of operations.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Moreover, we continue to receive results from meta-analyses or previously initiated clinical
trials using ESAs, including PMCs, and adverse results could negatively impact the use and sales of
our ESAs. For example, in September&nbsp;2008, we announced that we had received a summary of
preliminary results from the Cochrane Collaboration&#146;s independent meta-analysis of patient-level
data from previously conducted, randomized, controlled, clinical studies evaluating ESAs in cancer
patients which we submitted to the FDA and the EMA. This Cochrane meta-analysis of patient-level
data from previous studies corroborates prior analyses indicating that the use of ESAs may increase
the risk of death in cancer patients. The studies in the analysis all predate the current label,
which advises using the least amount of ESA necessary to avoid transfusion but they do not exclude
the potential for adverse outcomes when ESAs are prescribed according to the current label.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Our sales depend on coverage and reimbursement from third-party payers.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Sales of all of our principal products are dependent on the availability and extent of
coverage and reimbursement from third-party payers, including government healthcare programs and
private insurance plans. Governments and private payers may regulate prices, reimbursement levels
and/or access to our products to control costs or to affect levels of use of our products. We rely
in large part on the reimbursement of our principal products through government programs such as
Medicare and Medicaid in the United States and similar programs in foreign countries and a
reduction in the coverage and/or reimbursement for our products could have a material adverse
effect on our product sales and results of operations.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">The government-sponsored healthcare systems in Europe and many other foreign countries
are the primary payers for healthcare expenditures, including payment for drugs and biologics, in
those regions. While mandatory price reductions have been a recurring aspect of business for the
pharmaceutical and biotechnology industries in the EU, given the current worldwide economic
conditions, certain EU country governments have increased the frequency and size of such mandatory
price reductions to extract further cost savings. For example, countries such as Greece, Germany
and Spain, among others, have announced price reductions and/or mandated rebates for certain
pharmaceutical and biological products. Other countries may follow and/or take similar or more
extensive actions to reduce expenditure on drugs and biologics, including mandatory price
reductions, preference for biosimilar products or reduction in the amount of reimbursement. While
we cannot fully predict the impact the recent price reductions will have on our business or predict
the extent of further price reductions by countries in Europe, such reductions in price and/or the
coverage and reimbursement for our products in European countries could have a material adverse
effect on our product sales and results of operations.

</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In March, 2010 the PPACA and the companion Healthcare and Education Reconciliation Act, which
made certain changes and adjustments to the PPACA, primarily with respect to the PPACA&#146;s financial
and budgetary impacts, were signed into law. A major goal of the new healthcare reform law is to
provide greater access to healthcare coverage for more Americans. Accordingly, the new healthcare
reform law requires individual U.S. citizens and legal residents to maintain qualifying health
coverage, imposes certain requirements on employers with respect to offering health coverage to
employees, amends insurance regulations regarding when coverage can be provided and denied to
individuals, and expands existing government healthcare coverage programs to more individuals in
more situations. While we do not expect a significant increase in sales of our products as a
result of the expansion in healthcare coverage, the new healthcare reform law does have several
components, with varied implementation timelines, that are expected to adversely impact our
business. While we cannot fully predict the ultimate impact the new healthcare reform law will
have on us, we expect that the new law will have a material adverse effect on our business and
results of operations.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Public and private insurers have pursued, and continue to pursue, aggressive cost containment
initiatives, including increased focus on comparing the effectiveness, benefits and costs of
similar treatments, which could result in lower reimbursement rates for our products. A substantial portion of our U.S. business relies on reimbursement under Medicare Part&nbsp;B
coverage. Any deterioration in the timeliness or certainty of payment
from CMS to physicians,
including as a result of changes in policy or regulations, or as a result of operational
difficulties, could negatively impact the willingness of physicians to prescribe our products for
patients relying on Medicare for their medical coverage.
 Most of our
products furnished to Medicare beneficiaries in both a physician office setting and hospital
outpatient setting are reimbursed under the Average Sales Price (&#147;ASP&#148;) payment methodology.
ASP-based reimbursements of products under Medicare may be below or could fall below the cost that
some medical providers pay for such products, which would adversely affect sales of our products.
For example, the ASP payment rate for most of our products furnished in the hospital outpatient
setting has been reduced twice since 2007. We also face certain risks relating to the calculation
of ASP. ASP is calculated by the manufacturer based on a statutorily defined formula and submitted
to CMS. However, the statute, regulations and CMS guidance do not define specific methodologies for
all aspects of the calculation of ASP. For example, in the Medicare Physician Fee Schedule&nbsp;Final
Rule for 2010,
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">CMS did not address a proposed methodology for treatment of bundled price concessions.
Consequently, the current CMS guidance is that manufacturers may make &#147;reasonable assumptions&#148; in
their calculation of ASP consistent with the general requirements and the intent of the Medicare
statute, federal regulations and their customary business practices. As a result, we are required
to apply our judgment in certain aspects of calculating ASP which are disclosed to CMS and also are
subject to further CMS review. If our calculation of ASP is incorrect, we could be subject to
substantial fines and penalties which could have a material adverse impact on our results of
operations.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Other initiatives reviewing the coverage or reimbursement of our products could result in less
extensive coverage or lower reimbursement rates. For example, in July&nbsp;2007, CMS issued a national
coverage decision (&#147;NCD&#148;) where it determined that ESA treatment was not reasonable and necessary
for certain clinical conditions and established Medicare coverage parameters for FDA-approved ESA
use in oncology. We believe the restrictions in the NCD on the coverage and reimbursement of ESAs
has had a material adverse effect on the use, reimbursement and sales of Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, which
has had a significant impact to our business. We believe that the NCD may continue to impact us in
the future.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On March&nbsp;24, 2010, CMS held a MEDCAC meeting to examine the currently available evidence on
the use of ESAs to manage anemia in patients who have CKD, although there was no clear outcome from
the MEDCAC meeting. Additionally, on June&nbsp;16, 2010, CMS opened a NCA for the use of ESAs to manage
anemia in patients with CKD and dialysis-related anemia. This NCA initiates the process of
reviewing and evaluating potential changes in Medicare coverage policies for the use of ESAs in
these patients and may result in the issuance of a NCD by CMS. Generally, a NCD is a national
policy statement granting, limiting or excluding Medicare coverage or reimbursement for a specific
medical item or service. The 30-day public comment period on the NCA ended on July&nbsp;17, 2010 and
CMS has stated that the NCA process for ESAs will conclude on or before June&nbsp;16, 2011, but CMS
could propose a NCD at any time prior to that deadline. We cannot predict if and when a NCD will
be issued or the details of any potentially changed coverage decisions for the use of ESAs in
patients with CKD. However, similar to the impact of the NCD on the use of ESAs in oncology, the
NCA or a NCD around the use of ESAs to manage anemia in patients with CKD and dialysis-related
anemia may negatively affect use, coverage and reimbursement, and/or product sales of our ESA
products in the nephrology setting.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Further,
the list of potential future NCDs issued by CMS in late 2008 included the category of
thrombopoiesis stimulating agents (platelet growth factors), the category of drugs that includes
Nplate<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, and a discussion on bisphosphonates used to treat osteoporosis. CMS has not
announced whether it will proceed with a NCD related to thrombopoiesis stimulating agents and,
while Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> is not a bisphosphonate, there is the possibility for CMS to evaluate
other osteoporosis agents, including RANK Ligand inhibitors such as Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In the dialysis setting, the reimbursement rates for our products may also be subject to
downward pressure. In the United States, dialysis providers are primarily reimbursed for
EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> by the federal government through the ESRD Program of Medicare. The ESRD Program
reimburses approved dialysis providers for 80% of allowed dialysis costs while the remainder is
paid by other sources, including patients, state Medicaid programs, private insurance, and to a
lesser extent, state kidney patient programs. The ESRD Program reimbursement methodology is
established by federal law and is monitored and implemented by CMS. Since April&nbsp;2006, the Medicare
reimbursement for ESAs administered to dialysis patients has been subject to an Erythropoietin
Monitoring Policy (&#147;EMP&#148;), the Medicare payment review mechanism used by CMS to monitor EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and
Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> utilization and hematocrit outcomes of dialysis patients. CMS revised the EMP, effective
January&nbsp;2008, further limiting reimbursement for EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in
certain cases. Further reduction in reimbursement in the dialysis setting could have a material
adverse effect on sales of EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, and our business.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Additional initiatives addressing the coverage or reimbursement of our products could result
in less extensive coverage or lower reimbursement, which could negatively affect sales of our
products. For example, on July&nbsp;26, 2010, CMS released its final rule to implement a bundled
prospective payment system for ESRD facilities as required by the 2008 Medicare Improvements for
Patients and Providers Act (&#147;MIPPA&#148;). As a result, the implementation of the bundled payment system
for ESRD facilities could have a material adverse impact on the coverage and reimbursement, use and
sales of EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> beginning in 2011, and Sensipar<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> beginning in 2014.
Healthcare providers may narrow the circumstances in which they prescribe or administer our
products if reimbursement rates are reduced or in anticipation of reimbursement being reduced,
which could reduce the use and/or price of our products. A reduction in the use or price of our
products could have a material adverse effect on us and our results of operations.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%"><I>If our intellectual property positions are challenged, invalidated, circumvented or expire,
or if we fail to prevail in present and future intellectual property litigation, our business
could be adversely affected.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Our success depends in part on our ability to obtain and defend patent rights and other
intellectual property rights that are important to the commercialization of our products and
product candidates. The patent positions of pharmaceutical and biotechnology companies can be
highly uncertain and often involve complex legal, scientific and factual questions. Third parties
may challenge, invalidate or circumvent our patents and patent applications relating to our
products, product candidates and technologies. In addition, our patent positions might not protect
us against competitors with similar products or technologies because competing products or
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">technologies may not infringe our patents. For certain of our product candidates, there are
third parties who have patents or pending patent applications that they may claim necessitate
payment of a royalty or prevent us from commercializing these product candidates in certain
territories. Patent disputes are frequent, costly and can preclude, delay or increase the cost of
commercialization of products. We are currently, and in the future may be, involved in patent
litigation. A patent dispute or litigation may not discourage a potential violator from bringing
the product that is alleged to infringe to market prior to a final resolution of the dispute or
litigation. For example, despite the ongoing litigation, Teva Pharmaceuticals USA, Inc. (&#147;Teva&#148;)
has stated that it intends to sell its filgrastim product, upon
approval from the FDA, in the United States
without a license from us and prior to the expiration of our G-CSF patents. Further, Teva and Barr Laboratories, Inc. may seek to launch a generic version of
Sensipar<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> prior to the final resolution of the ANDA litigation once the stay upon action by the FDA expires in September&nbsp;2011.
 The period of time from
inception until resolution of a patent dispute or litigation is subject to the availability and
schedule of the court, agency or tribunal before which the dispute or litigation is pending. We
may be subject to competition during this period and may not be able to fully recover for the
losses, damages, and harms we incur from infringement by the competitor product even if we prevail.
Moreover, if we lose or settle current or future litigations at certain stages or entirely, we
could be subject to competition and/or significant liabilities, be required to enter into
third-party licenses for the infringed product or technology or be required to cease using the
technology or product in dispute. In addition, we cannot guarantee that such licenses will be
available on terms acceptable to us, or at all.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Further, under the Hatch-Waxman Act, products approved by the FDA under a NDA may be the
subject of patent litigation with generic competitors before the five year period of data
exclusivity provided for under the Hatch-Waxman Act has expired and prior to the expiration of the
patents listed for the product.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In recent years, policymakers have proposed reforming U.S. patent laws and regulations. For
example, patent reform legislation was introduced in both houses of the U.S. Congress in 2009, and
the Senate Judiciary Committee approved a patent reform bill on April&nbsp;2, 2009. In general, the
proposed legislation attempts to address issues surrounding the increase in patent litigation by,
among other things, establishing new procedures for challenging patents. While we cannot predict
what form any new patent reform laws or regulations ultimately may take, final legislation could
introduce new substantive rules and procedures for challenging patents, and certain reforms that
make it easier for competitors to challenge our patents could have a material adverse effect on our
business.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>We expect to face increasing competition from biosimilar products which could impact our
profitability.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We currently face competition in Europe from biosimilar products, and we expect to face
increasing competition from biosimilars in the future. Lawmakers in the United States have recently
enacted healthcare reform legislation which included an abbreviated regulatory pathway for the
approval of biosimilars. The EU has already created such a regulatory pathway. To the extent that
governments adopt more permissive approval frameworks and competitors are able to obtain broader
marketing approval for biosimilars, our products will become subject to increased competition.
Expiration or successful challenge of applicable patent rights could trigger such competition, and
we could face more litigation regarding the validity and/or scope of our patents.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In the EU, the EC has granted marketing authorizations for several biosimilars pursuant to a
set of general and product class-specific guidelines for biosimilar approvals issued over the past
few years. In 2006, the EMA developed and issued final regulatory guidelines related to the
development and approval of biosimilar products. The final guidelines included clinical trial
guidance for certain biosimilar products, including erythropoietins and G-CSFs, recommending that
applicants seeking approval of such biosimilar products conduct pharmacodynamic, toxicological and
clinical safety studies as well as a pharmacovigilance program. Some companies have received and
other companies are seeking approval to market erythropoietin and G-CSF biosimilars in the EU,
presenting additional competition for our products. (See &#151; <I>&#147;Our marketed products face substantial
competition.&#148;</I>) For example, following the expiration of the principal European patent relating to
recombinant G-CSF in August&nbsp;2006, the EC issued marketing authorizations for the first G-CSF
biosimilar products and the product was launched in certain EU countries in 2008 and 2009. There
are several G-CSF biosimilars available in the EU marketed by different companies and these G-CSF
biosimilar products compete with NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>
and Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. Further, as in an
effort to reduce costs, countries in the EU may in the future permit
the automatic substitution by pharmacists of biosimilars for the
corresponding
innovator products. We cannot predict to what extent the entry of
biosimilar products or other competing products will impact future sales of our products in the EU.
Our inability to compete effectively could reduce sales, which could have a material adverse effect
on our results of operations.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">On March&nbsp;23, 2010, President Obama signed into law the PPACA which authorized the FDA to
approve biosimilar products. The new law established a period of 12&nbsp;years of data exclusivity for
reference products in order to preserve incentives for future innovation and outlined statutory
criteria for science-based biosimilar approval standards that take into account patient safety
considerations. Under this framework, data exclusivity protects the data in the innovator&#146;s
regulatory application by prohibiting, for a period of 12&nbsp;years, others from gaining FDA approval
based in part on reliance or reference to the innovator&#146;s data in their application to the FDA.
The next phase of the process will be implementation of the biosimilars regulatory approval pathway
by the FDA. The new law does not change the duration of patents granted on biologic products. While
the FDA now has the authority to approve biosimilar products, the FDA has not announced whether
they will first publish guidance or rules for biosimilar applicants before approving biosimilar
products. With the likely introduction of biosimilars in the United States, we may in the future
face greater
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">competition from biosimilar products and downward pressure on our product prices, sales and
revenues, subject to our ability to enforce our patents. Further, biosimilar manufacturers with
approved products in Europe may seek to quickly obtain U.S. approval now that the regulatory
pathway for biosimilars has been enacted.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%"><I>We must conduct clinical trials in humans before we can commercialize and sell any of our
product candidates or existing products for new indications.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Before we can sell any products, we must conduct clinical trials to demonstrate that our
product candidates are safe and effective for use in humans. The results of these clinical trials
are used as the basis to obtain regulatory approval from regulatory authorities such as the FDA<I>.</I>
(See &#151; <I>&#147;Our current products and products in development cannot be sold if we do not gain or
maintain regulatory approval.&#148;</I>) We are required to conduct clinical trials using an appropriate
number of trial sites and patients to support the product label claims. The length of time, number
of trial sites and patients required for clinical trials vary substantially and therefore, we may
spend several years and incur substantial expense in completing certain clinical trials. Delays in
planned clinical trials can result in increased development costs, delays in regulatory approvals,
associated delays in product candidates reaching the market and revisions to existing product
labels. For example, in 2006 we delayed the start of our phase 3 trial in first-line NSCLC due to
an increased frequency of cholecystitis (inflammation of the gall bladder) in patients treated with
our late-stage product candidate motesanib. Following initiation of the trial in November&nbsp;2008,
enrollment in this phase 3 trial was temporarily suspended following a planned safety data review
of 600 patients by the study&#146;s independent DMC. In February&nbsp;2009, the DMC recommended the trial
resume enrollment of patients with non-squamous NSCLC only, and in June&nbsp;2009, we reinitiated
enrollment in this patient population following an FDA-approved revision to the study protocol.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In addition, in order to increase the number of patients available for enrollment for our
clinical trials, we have and will continue to open clinical sites and enroll patients in a number
of new geographic locations where our experience conducting clinical trials is more limited,
including Russia, India, East Asia and some Central and South American countries either through
utilization of third-party contract clinical trial providers entirely or in combination with local
staff. Conducting clinical trials in locations where we have limited experience requires
substantial time and resources to identify and understand the unique regulatory environments of
individual countries. Further, we must ensure the timely production, distribution and delivery of the clinical
supply of our product candidates to the numerous and varied clinical trial sites. If we fail to
adequately manage the design, execution and regulatory aspects of our large, complex and regulatory
diverse clinical trials or manage the production or distribution of our clinical supply, corresponding regulatory
approvals may be delayed or we may fail to gain approval for our product candidates or could lose
our ability to market existing products in certain therapeutic areas or altogether. If we are
unable to market and sell our product candidates or are unable to obtain approvals in the timeframe
needed to execute our product strategies, our business and results of operations would be
materially adversely affected. Additional information on our clinical trials can be found on our
website at www.amgen.com. (This website address is not intended to function as a hyperlink, and the
information contained on our website is not intended to be a part of this filing.)
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Patients may also suffer adverse medical events or side effects in the course of our, our
licensees, partners or independent investigator&#146;s clinical trials which could:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>delay the clinical trial program</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>require additional or longer trials to gain approval</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>prohibit regulatory approval of our product candidates or new indications for existing
products</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>render the product candidate commercially unfeasible or limit our ability to market
existing products completely or in certain therapeutic areas.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Clinical trials must be designed based on the current standard of medical care. However in
certain diseases, such as cancer, the standard of care is evolving rapidly. In these diseases, the
duration of time needed to complete certain clinical trials may result in the design of such
clinical trials being based on an out of date standard of medical care, limiting the utility and
application of such trials. We may not obtain favorable clinical trial results and may not be able
to obtain regulatory approval for new product candidates, new indications for existing products or
maintenance of our current labels on this basis. Further, clinical trials conducted by others,
including our licensees, partners or independent investigators, may result in unfavorable clinical
trials results that may call into question the safety of our products in off-label or on label uses
that may result in label restrictions and/or additional trials.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Even after a product is on the market, safety concerns may require additional or more
extensive clinical trials as part of a pharmacovigilance program of our product or for approval of
a new indication. For example, we are moving forward with Study 782 as part of our
Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> pharmacovigilance program. (See &#151; <I>&#147;Our ESA products continue to be under
review and receive scrutiny by regulatory authorities.</I>&#148;) Additional clinical trials we initiate,
including those required by the FDA, could result in substantial additional expense and the
outcomes could result in additional label restrictions or the loss of regulatory approval for an
approved
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">indication, each of which may have a material adverse effect on our business and results of
operations. Additionally, any negative results from such trials could materially affect the extent
of approvals, the use, reimbursement and sales of our products.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>We may not be able to develop commercial products.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Successful product development in the biotechnology industry is highly uncertain, and very few
R&#038;D projects produce a commercial product. We intend to continue to make significant R&#038;D
investments. Product candidates or new indications for existing products (collectively, &#147;product
candidates&#148;) that appear promising in the early phases of development may fail to reach the market
for a number of reasons, such as:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the product candidate did not demonstrate acceptable clinical trial results even though
it demonstrated positive preclinical trial results, for reasons that could include changes
in the standard of care of medicine</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the product candidate was not effective or more effective than currently available
therapies in treating a specified condition or illness</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the product candidate is not cost effective in light of existing therapeutics</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the product candidate had harmful side effects in humans or animals</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the necessary regulatory bodies, such as the FDA, did not approve our product candidate
for an intended use</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the product candidate was not economical for us to manufacture and commercialize</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>other parties have or may have proprietary rights relating to our product candidate,
such as patent rights, and will not let us sell it on reasonable terms, or at all</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>we and certain of our licensees, partners or independent investigators may fail to
effectively conduct clinical development or clinical manufacturing activities</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the regulatory pathway to approval for product candidates is uncertain or not
well-defined</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">For example, after discussions with the FDA we have decided not to file for approval of
motesanib in refractory thyroid cancer until there is more clarity on what would constitute an
appropriate regulatory filing package for that indication. Further, several of our product
candidates have failed or been discontinued at various stages in the product development process.
For example, in June&nbsp;2004, we announced that the phase 2 study of Glial Cell Lined-Derived
Neurotrophic Factor (&#147;GDNF&#148;) for the treatment of advanced Parkinson&#146;s disease did not meet the
primary study endpoint upon completion of nine months of the double-blind treatment phase of the
study. The conclusion was reached even though a small phase 1 pilot investigator-initiated
open-label study over a three-year period appeared to result in improvements for advanced
Parkinson&#146;s disease patients. Subsequently, we discontinued clinical development of GDNF in
patients with advanced Parkinson&#146;s disease.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>Our business may be affected by litigation and government investigations.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We and certain of our subsidiaries are involved in legal proceedings. (See Note,
&#147;<I>Contingencies and commitments</I>&#148; in the notes to our consolidated financial statements in our annual
and quarterly reports). Civil and criminal litigation is inherently unpredictable, and the outcome
can result in excessive verdicts, fines, penalties, exclusion from
the federal healthcare programs and/or injunctive relief that affect how we
operate our business. Defense of litigation claims can be expensive, time-consuming and distracting
and it is possible that we could incur judgments or enter into settlements of claims for monetary
damages or change the way we operate our business, which could have a material adverse effect on
our results of operations, financial position or cash flows. In addition, product liability is a
major risk in testing and marketing biotechnology and pharmaceutical products. We may face
substantial product liability exposure in human clinical trials and for products that we sell after
regulatory approval. Product liability claims, regardless of their merits, could be costly and
divert management&#146;s attention, and adversely affect our reputation and the demand for our products.
Amgen and Immunex have previously been named as defendants in product liability actions for certain
of our products.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We are also involved in government investigations that arise in the ordinary course of our
business. We have received subpoenas from a number of government entities, including the U.S.
Attorney&#146;s Offices for the Eastern District of New York and the Western District of Washington, as
well as the Attorneys General of New York and New Jersey. The federal subpoenas have been issued
pursuant to the Health Insurance Portability and Accountability Act of 1996 (18 U.S.C. 3486), and
by a federal grand jury, while the Attorneys General subpoenas have been issued pursuant to state
specific statutes relating to consumer fraud laws and state false claims
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">acts. The government is allowed to use materials produced in response to a section 3486
administrative subpoena in both criminal and civil investigations. In general, the subpoenas
request documents relating to the sales and marketing of our products, and our collection and
dissemination of information reflecting clinical research as to the safety and efficacy of our
ESAs. Based on representations in a U.S. government filing, that became public in May&nbsp;2009 relating
to the Massachusetts Qui Tam Action, we now believe the subpoenas we received from the U.S.
Attorney&#146;s Offices for the Eastern District of New York and the Western District of Washington also
relate to nine additional Qui Tam Actions which are purportedly pending against Amgen, including
eight pending in the U.S. District Court for the Eastern District of New York and one pending in
the U.S. District Court for the Western District of Washington. The U.S. government filing further
alleges that a large number of states are involved in the Qui Tam investigations, led by the State
of New York. These investigations are represented to be joint criminal and civil investigations.
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Throughout these investigations, and in litigation, the government entities are asserting that
we violated various state and federal laws. These investigations are very burdensome, expensive
and time-consuming for us to explain and defend to these entities. Although we cannot predict
whether additional proceedings may be initiated against us, or predict when these matters may be
resolved, it is not unusual for investigations such as these to continue for a considerable period
of time and to require management&#146;s attention and significant legal expense. A determination that
we are in violation of the various federal and state laws that govern the sales and marketing of
our products could result in federal criminal liability and/or federal or state civil or
administrative liability, and thus could result in substantial financial damages or criminal
penalties and possible exclusion from future participation in the Medicare and Medicaid programs.
In addition, we may see new governmental investigations of or actions against us citing novel
theories of recovery. Any of these results could have a material adverse effect on our results of
operations, financial position or cash flows in the period in which such liabilities are incurred.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%"><I>We rely on single-source third-party suppliers for certain of our raw materials, medical
devices and components.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We rely on single-source unaffiliated third-party suppliers for certain raw materials, medical
devices and components necessary for the formulation, fill and finish of our products. Certain of
these raw materials, medical devices and components are the proprietary products of these
unaffiliated third-party suppliers and are specifically cited in our drug application with
regulatory agencies so that they must be obtained from that specific sole source and could not be
obtained from another supplier unless and until the regulatory agency approved such supplier.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Among the reasons we may be unable to obtain these raw materials, medical devices and
components include:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>regulatory requirements or action by regulatory agencies or others</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>adverse financial or other strategic developments at or affecting the supplier</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>unexpected demand for or shortage of raw materials, medical devices or components</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>labor disputes or shortages, including the effects of a pandemic flu outbreak, natural
disaster, or otherwise</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>failure to comply with our quality standards which results in quality and product
failures, product contamination and/or recall</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">These events could adversely affect our ability to satisfy demand for our products, which
could adversely affect our product sales and operating results materially. For example, we have
experienced shortages in certain components necessary for the formulation, fill and finish of
certain of our products in our Puerto Rico facility without impact on our ability to supply these
products. However, we may experience these or other shortages in the future resulting in delayed
shipments, supply constraints, contract disputes and/or stock-outs of our products. Also, certain
of the raw materials required in the commercial and clinical manufacturing and the formulation of
our products are sourced from other countries and/or derived from biological sources, including
mammalian tissues. In addition, one of our marketed products also includes bovine serum and HSA.
Some countries in which we market our products may restrict the use of certain biologically derived
substances in the manufacture of drugs. We continue to investigate alternatives to certain
biological sources and alternative manufacturing processes that do not require the use of certain
biologically derived substances as such raw materials may be subject to contamination and/or
recall.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">A material shortage, contamination, recall and/or restriction of the use of certain
biologically derived substances or other raw materials, which may be sourced from other countries,
used in the manufacture of our products could adversely impact or disrupt our commercial
manufacturing of our products or could result in a mandated withdrawal of our products from the
market. This could adversely affect our ability to satisfy demand for our products, which could
adversely affect our product sales and operating results materially. Further, any disruptions or
delays by us or by third-party suppliers or partners in converting to alternatives to certain
biologically derived substances and alternative manufacturing processes or our ability to gain
regulatory approval for the alternative
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">materials and manufacturing processes could increase our associated costs or result in the
recognition of an impairment in the carrying value of certain related assets, which could have a
material and adverse affect on our results of operations.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%"><I>Manufacturing difficulties, disruptions or delays could limit supply of our products and limit
our product sales.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Manufacturing biologic human therapeutic products is difficult, complex and highly regulated.
We currently manufacture all of our principal products and plan to manufacture many of our product
candidates. In addition, we currently use third-party contract manufacturers to produce or assist
in the production of ENBREL, Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP>, Sensipar<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>/Mimpara<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and
Nplate<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and plan to use contract manufacturers to produce a number of our other
late-stage product candidates. Our ability to adequately and timely manufacture and supply our
products is dependent on the uninterrupted and efficient operation of our facilities and those of
our third-party contract manufacturers, which may be impacted by:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>availability or contamination of raw materials and components used in the manufacturing
process, particularly those for which we have no other source or supplier</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>capacity of our facilities and those of our contract manufacturers</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>contamination by microorganisms or viruses</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>natural or other disasters, including hurricanes, earthquakes
or fires</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>labor disputes or shortages, including the effects of a pandemic flu outbreak, natural
disaster, or otherwise</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>degree of compliance with regulatory requirements</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>changes in forecasts of future demand</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>timing and actual number of production runs</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>updating of manufacturing specifications</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>production success rates and yields</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>timing and outcome of product quality testing</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">If the efficient manufacture and supply of our products is interrupted, we may experience
delayed shipments, supply constraints, stock-outs and/or recalls of our products. If we are at any
time unable to provide an uninterrupted supply of our products to patients, we may lose patients
and physicians may elect to prescribe competing therapeutics instead of our products, which could
materially and adversely affect our product sales and results of operations.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Our manufacturing processes and those of our third-party contract manufacturers must undergo a
potentially lengthy FDA or other regulatory approval process and are subject to continued review by
the FDA and other regulatory authorities. It can take longer than five years to build and license a
new manufacturing plant and it can take longer than three years to qualify and license a new
contract manufacturer. In order to maintain supply, mitigate risks associated with the majority of
our formulation, fill and finish operations being performed in a single facility and to satisfy
anticipated demand we must successfully implement certain manufacturing projects on schedule.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">If regulatory authorities determine that we or our third-party contract manufacturers or
certain of our third-party service providers have violated regulations or if they restrict, suspend
or revoke our prior approvals, they could prohibit us from manufacturing our products or conducting
clinical trials or selling our marketed products until we or the affected third-party contract
manufacturers or third-party service providers comply, or indefinitely. Because our third-party
contract manufacturers and certain of our third-party service providers are subject to the FDA and
foreign regulatory authorities, alternative qualified third-party contract manufacturers and
third-party service providers may not be available on a timely basis or at all. If we or our
third-party contract manufacturers or third-party service providers cease or interrupt production
or if our third-party contract manufacturers and third-party service providers fail to supply
materials, products or services to us, we may experience delayed shipments, supply constraints,
stock-outs and/or recalls of our products. Additionally, we distribute a substantial volume of our
commercial products through a single distribution center in Louisville, Kentucky for the United
States and another in Breda, the Netherlands for Europe and much of the rest of the world. We also conduct all the labeling and packaging of our products distributed in Europe and much
of the rest of the world in Breda, the Netherlands. Our ability to timely supply products is
dependent on the uninterrupted and efficient operations of our distribution and logistics
centers, our third-party logistics providers and our labeling and packaging facility
in Breda. Further, we rely on commercial transportation for the distribution of our products to our
customers which may be negatively impacted by natural disasters, such as earthquakes or volcanic
eruptions, or security threats.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%"><I>We manufacture and formulate, fill and finish substantially all our products at our Puerto
Rico manufacturing facility and manufacture and formulate, fill and finish substantially
all of our clinical supply at our Thousand Oaks, California manufacturing facility; if
significant natural disasters or production failures occur at the Puerto Rico
facility, we may not be able to supply these products or, at the Thousand Oaks facility,
we may not be able to continue our clinical trials.</I>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">We currently perform all of the formulation, fill and finish for EPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>,
Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> and
substantially all of the formulation, fill and finish operations for ENBREL, and all of the bulk
manufacturing for Aranesp<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>, Neulasta<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> and NEUPOGEN<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> at our
manufacturing facility in Juncos, Puerto Rico. In addition, upon licensure by the FDA, bulk
material for Prolia<SUP style="FONT-size: 85%; vertical-align: text-top">TM</SUP> will be produced at the Puerto Rico facility.
We also perform all of the bulk manufacturing and formulation, fill and finish, and
packaging for product candidates to be used in clinical trials at our manufacturing facility in
Thousand Oaks, California. The global supply of our products and product candidates
is significantly dependent on the uninterrupted and efficient operation of these
facilities. A number of factors could adversely affect our operations, including:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>power failures and/or other utility failures</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>breakdown, failure or substandard performance of equipment</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>improper installation or operation of equipment</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>labor disputes or shortages, including the effects of a pandemic flu outbreak</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>inability or unwillingness of third-party suppliers to provide raw materials and
components</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>natural or other disasters, including hurricanes, earthquakes
or fires</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="2%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>failures to comply with regulatory requirements, including those of the FDA</TD>
</TR>

</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">In the past, the Puerto Rico facility has experienced manufacturing component shortages and
there was evidence of adverse trends in the microbial bioburden of the production environment that
reduced the production output. The same or other problems may result in our being unable to supply
these products, which could adversely affect our product sales and operating results materially.
Although we have obtained limited insurance to protect against certain business interruption
losses, there can be no assurance that such coverage will be adequate or that such coverage will
continue to remain available on acceptable terms, if at all. The extent of the coverage of our
insurance could limit our ability to mitigate for lost sales and such losses could materially
adversely affect our product sales and operating results. Our Puerto Rico facility is also subject
to the same difficulties, disruptions or delays in manufacturing experienced in our other
manufacturing facilities. For example, the limited number of lots of ENBREL voluntarily recalled in
September&nbsp;2009 were manufactured at our Puerto Rico facility and we have made commitments to the
FDA to address the causes behind the recall. In future inspections, our failure to adequately
address the FDA&#146;s expectations could lead to further inspections of the facility or regulatory
actions. (See &#151; <i>&#147;Manufacturing difficulties, disruptions or delays could limit supply of our
products and limit our product sales.&#148;</i>)
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="112"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Repurchases under our stock repurchase program reflects, in part, our confidence in the
long-term value of our common stock. Additionally, we believe that it is an effective way of
returning cash to our stockholders. The manner of purchases, the amount we spend and the number of
shares repurchased will vary based on a number of factors including the stock price, blackout
periods during which we are restricted from repurchasing shares, and our credit rating and may
include private block purchases as well as market transactions.
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">A summary of our repurchase activity for the three months ended June&nbsp;30, 2010 is as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="18%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total number of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Maximum $ value</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total number</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Average</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>shares purchased</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>that may yet be</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>of shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>price paid</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>as part of publicly</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>purchased under the</B></TD>
    <TD></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>purchased</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>per share</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>announced programs</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>programs</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></TD>
    <TD></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">April 1 - April&nbsp;30</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,313,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">59.71</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,313,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,663,418,915</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">May 1 - May&nbsp;31</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,663,418,915</TD>
    <TD></TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">June 1 - June&nbsp;30</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,663,418,915</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,313,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59.71</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,313,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;text-align:justify">
<TR>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="FONT-size: 85%; vertical-align: text-top">(1)</SUP></TD>
    <TD>&nbsp;</TD>
    <TD> In December&nbsp;2009, the Board of Directors authorized us to repurchase up to
an additional $5.0&nbsp;billion of our common stock. As of June&nbsp;30, 2010, we had $3.7&nbsp;billion
available for stock repurchases as authorized by our Board of Directors.</TD>
</TR>

</TABLE>


<DIV align="left">
<A name="113"></A>
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;6.&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>EXHIBITS</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Reference is made to the Index to Exhibits included herein.
</DIV>

<P align="center" style="font-size: 12pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left">
<A name="114"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="Justify" style="font-size: 10pt; margin-top: 10pt; text-indent:8%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Amgen Inc.<BR>
(Registrant)<BR>
&nbsp;</TD>
    <TD></TD>
</TR><TR>
    <TD align="left">Date: August 9, 2010</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="center">
/s/ Michael A. Kelly
&nbsp;</TD>
    <TD></TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center">Michael A. Kelly&nbsp;</TD>
    <TD></TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center">Acting Chief Financial Officer&nbsp;</TD>
    <TD></TD>
</TR>

</TABLE>

<P align="center" style="font-size: 12pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AMGEN INC.</B>
</DIV>

<DIV align="left">
<A name="115"></A>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>INDEX TO EXHIBITS</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">3.1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Restated Certificate of Incorporation (As Restated December&nbsp;6, 2005). (Filed as
an exhibit to Form&nbsp;10-K for the year ended December&nbsp;31, 2005 on March&nbsp;10, 2006
and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Certificate of Amendment of the Restated Certificate of Incorporation (As
Amended May&nbsp;24, 2007). (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended
June&nbsp;30, 2007 on August&nbsp;9, 2007 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.3</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Certificate of Correction of the Restated Certificate of Incorporation (As
Corrected May&nbsp;24, 2007). (Filed as an exhibit to Form&nbsp;10-Q for the quarter
ended June&nbsp;30, 2007 on August&nbsp;9, 2007 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.4</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Certificate of Elimination of the Certificate of Designations of the Series&nbsp;A
Junior Participating Preferred Stock (As Eliminated December&nbsp;10, 2008). (Filed
as an exhibit to Form&nbsp;10-K for the year ended December&nbsp;31, 2008 on February&nbsp;27,
2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.5</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Certificate of Amendment of the Restated Certificate of Incorporation (As
Amended May&nbsp;11, 2009). (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended
June&nbsp;30, 2009 on August&nbsp;10, 2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.6</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Certificate of Correction of the Restated Certificate of Incorporation (As
Amended May&nbsp;11, 2009). (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended
June&nbsp;30, 2009 on August&nbsp;10, 2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.7*</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Certificate of Correction of the Restated Certificate of Incorporation (As
Amended May&nbsp;13, 2010).</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">3.8</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amended and Restated Bylaws of Amgen Inc. (As Amended and Restated October&nbsp;6,
2009). (Filed as an exhibit to Form&nbsp;8-K filed on October&nbsp;7, 2009 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.1</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of stock certificate for the common stock, par value $.0001 of the
Company. (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended March&nbsp;31, 1997
on May&nbsp;13, 1997 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.2</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of Indenture, dated January&nbsp;1, 1992. (Filed as an exhibit to Form&nbsp;S-3
Registration Statement filed on December&nbsp;19, 1991 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.3</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Agreement of Resignation, Appointment and Acceptance dated February&nbsp;15, 2008.
(Filed as an exhibit to Form&nbsp;10-K for the year ended December&nbsp;31, 2007 on
February&nbsp;28, 2008 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.4</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Two Agreements of Resignation, Appointment and Acceptance in the same form as
the previously filed Exhibit&nbsp;4.3 hereto are omitted pursuant to instruction 2
to Item&nbsp;601 of Regulation&nbsp;S-K. Each of these agreements, which are dated
December&nbsp;15, 2008, replaces the current trustee under the agreements listed as
Exhibits 4.9 and 4.16, respectively, with Bank of New York Mellon. Amgen Inc.
hereby agrees to furnish copies of these agreements to the Securities and
Exchange Commission upon request.</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.5</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">First Supplemental Indenture, dated February&nbsp;26, 1997. (Filed as an exhibit to
Form&nbsp;8-K on March&nbsp;14, 1997 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.6</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">8-1/8% Debentures due April&nbsp;1, 2097. (Filed as an exhibit to Form&nbsp;8-K filed on
April&nbsp;8, 1997 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.7</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Officer&#146;s Certificate, dated as of January&nbsp;1, 1992, as supplemented by the
First Supplemental Indenture, dated as of February&nbsp;26, 1997, establishing a
series of securities entitled &#147;8 1/8% Debentures due April&nbsp;1, 2097.&#148; (Filed as
an exhibit to Form&nbsp;8-K filed on April&nbsp;8, 1997 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.8</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of Liquid Yield Option&#153; Note due 2032. (Filed as an exhibit to Form&nbsp;8-K on
March&nbsp;1, 2002 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.9</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Indenture, dated as of March&nbsp;1, 2002. (Filed as an exhibit to Form&nbsp;8-K on March
1, 2002 and incorporated herein by reference.)</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">4.10</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">First Supplemental Indenture, dated March&nbsp;2, 2005. (Filed as an exhibit to Form
8-K filed on March&nbsp;4, 2005 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.11</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Indenture, dated as of August&nbsp;4, 2003. (Filed as an exhibit to Form&nbsp;S-3
Registration Statement on August&nbsp;4, 2003 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.12</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of 4.00% Senior Note due 2009. (Filed as an exhibit to Form&nbsp;8-K on
November&nbsp;19, 2004 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.13</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of 4.85% Senior Notes due 2014. (Filed as an exhibit to Form&nbsp;8-K on
November&nbsp;19, 2004 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.14</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Officers&#146; Certificate, dated November&nbsp;18, 2004, including forms of the 4.00%
Senior Notes due 2009 and 4.85% Senior Notes due 2014. (Filed as an exhibit to
Form&nbsp;8-K on November&nbsp;19, 2004 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.15</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of Zero Coupon Convertible Note due 2032. (Filed as an exhibit to Form&nbsp;8-K
on May&nbsp;6, 2005 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.16</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Indenture, dated as of May&nbsp;6, 2005. (Filed as an exhibit to Form&nbsp;8-K on May&nbsp;6,
2005 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.17</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Indenture, dated as of February&nbsp;17, 2006 and First Supplemental Indenture,
dated as of June&nbsp;8, 2006 (including form of 0.125% Convertible Senior Note due
2011). (Filed as exhibit to Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2006 on
August&nbsp;9, 2006 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.18</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Indenture, dated as of February&nbsp;17, 2006 and First Supplemental Indenture,
dated as of June&nbsp;8, 2006 (including form of 0.375% Convertible Senior Note due
2013). (Filed as exhibit to Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2006 on
August&nbsp;9, 2006 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.19</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Corporate Commercial Paper &#151; Master Note between and among Amgen Inc., as
Issuer, Cede &#038; Co., as Nominee of The Depository Trust Company, and Citibank,
N.A., as Paying Agent. (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended
March&nbsp;31, 1998 on May&nbsp;13, 1998 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.20</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Officers&#146; Certificate of Amgen Inc. dated as of May&nbsp;30, 2007, including forms
of the Company&#146;s Senior Floating Rate Notes due 2008, 5.85% Senior Notes due
2017 and 6.375% Senior Notes due 2037. (Filed as an exhibit to Form&nbsp;8-K on May
30, 2007 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.21</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Registration Rights Agreement, dated as of May&nbsp;30, 2007, among Amgen Inc. and
Morgan Stanley &#038; Co. Incorporated, Merrill Lynch, Pierce, Fenner &#038; Smith
Incorporated, Barclays Capital Inc., Credit Suisse Securities (USA)&nbsp;LLC,
Goldman, Sachs &#038; Co., Citigroup Global Markets Inc., J.P. Morgan Securities
Inc. and Lehman Brothers Inc. (Filed as an exhibit to Form&nbsp;8-K on May&nbsp;30, 2007
and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.22</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Officers&#146; Certificate of Amgen Inc. dated as of May&nbsp;23, 2008, including forms
of the Company&#146;s 6.15% Senior Notes due 2018 and 6.90% Senior Notes due 2038.
(Filed as exhibit to Form&nbsp;8-K on May&nbsp;23, 2009 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.23</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Officers&#146; Certificate of Amgen Inc. dated as of January&nbsp;16, 2009, including
forms of the Company&#146;s 5.70% Senior Notes due 2019 and 6.40% Senior Notes due
2039. (Filed as exhibit to Form&nbsp;8-K on January&nbsp;16, 2009 and incorporated herein
by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">4.24</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Officers&#146; Certificate of Amgen Inc. dated as of March&nbsp;12, 2010, including forms
of the Company&#146;s 4.50% Senior Notes due 2020 and 5.75% Senior Notes due 2040.
(Filed as exhibit to Form&nbsp;8-K on March&nbsp;15, 2010 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.1&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amgen Inc. 2009 Equity Incentive Plan. (Filed as Appendix&nbsp;A to Amgen Inc.&#146;s
Proxy Statement on March&nbsp;26, 2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.2&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of Stock Option Agreement and Restricted Stock Unit Agreement for the
Amgen Inc. 2009 Equity Incentive Plan. (Filed as an exhibit to Form&nbsp;10-Q for
the quarter ended March&nbsp;31, 2010 on May&nbsp;7, 2010).</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.3&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amgen Inc. 2009 Performance Award Program. (As Amended and Restated on December
4, 2009.) (Filed as an exhibit to Form&nbsp;10-K for the year ended December&nbsp;31,
2009, on March&nbsp;1, 2010 and incorporated herein by reference).</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">10.4&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of Performance Unit Agreement for the Amgen Inc. 2009 Performance Award
Program. (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2010
on May&nbsp;7, 2010).</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.5&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amgen Inc. 2009 Director Equity Incentive Program. (Filed as an exhibit to Form
8-K on May&nbsp;8, 2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.6&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Form of Grant of Non-Qualified Stock Option Agreement and Restricted Stock Unit
Agreement for the Amgen Inc. 2009 Director Equity Incentive Program. (Filed as
an exhibit to Form&nbsp;8-K on May&nbsp;8, 2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.7&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amgen Supplemental Retirement Plan. (As Amended and Restated effective January
1, 2009.) (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended September&nbsp;30,
2008 on November&nbsp;7, 2008 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.8&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment and Restatement of the Amgen Change of Control Severance Plan. (As
Amended December&nbsp;9, 2008.) (Filed as an exhibit to Form&nbsp;10-K for the year ended
December&nbsp;31, 2008 on February&nbsp;27, 2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.9&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amgen Inc. Executive Incentive Plan. (As Amended and Restated effective January
1, 2009.) (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended September&nbsp;30,
2008 on November&nbsp;7, 2008 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.10&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amgen Inc. Executive Nonqualified Retirement Plan. (As Amended and Restated
effective January&nbsp;1, 2009.) (Filed as an exhibit to Form&nbsp;10-Q for the quarter
ended September&nbsp;30, 2008 on November&nbsp;7, 2008 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.11&#043;*</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">First Amendment to the Amgen Inc. Executive Nonqualified Retirement Plan.</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.12&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amgen Nonqualified Deferred Compensation Plan. (As Amended and Restated
effective January&nbsp;1, 2009.) (Filed as an exhibit to Form&nbsp;10-Q for the quarter
ended September&nbsp;30, 2008 on November&nbsp;7, 2008 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.13&#043;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">2002 Special Severance Pay Plan for Amgen Employees. (Filed as an exhibit to
Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2002 on August&nbsp;13, 2002 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.14</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Product License Agreement, dated September&nbsp;30, 1985, and Technology License
Agreement, dated, September&nbsp;30, 1985 between Amgen and Ortho Pharmaceutical
Corporation. (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended June&nbsp;30,
2000 on August&nbsp;1, 2000 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.15</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Shareholders&#146; Agreement, dated May&nbsp;11, 1984, among Amgen, Kirin Brewery
Company, Limited and Kirin-Amgen, Inc. (Filed as an exhibit to Form&nbsp;10-K for
the year ended December&nbsp;31, 2000 on March&nbsp;7, 2001 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.16</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment No.&nbsp;1 dated March&nbsp;19, 1985, Amendment No.&nbsp;2 dated July&nbsp;29, 1985
(effective July&nbsp;1, 1985), and Amendment No.&nbsp;3, dated December&nbsp;19, 1985, to the
Shareholders&#146; Agreement dated May&nbsp;11, 1984. (Filed as an exhibit to Form&nbsp;10-Q
for the quarter ended June&nbsp;30, 2000 on August&nbsp;1, 2000 and incorporated herein
by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.17</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment No.&nbsp;4 dated October&nbsp;16, 1986 (effective July&nbsp;1, 1986), Amendment No.
5 dated December&nbsp;6, 1986 (effective July&nbsp;1, 1986), Amendment No.&nbsp;6 dated June
1, 1987, Amendment No.&nbsp;7 dated July&nbsp;17, 1987 (effective April&nbsp;1, 1987),
Amendment No.&nbsp;8 dated May&nbsp;28, 1993 (effective November&nbsp;13, 1990), Amendment No.
9 dated December&nbsp;9, 1994 (effective June&nbsp;14, 1994), Amendment No.&nbsp;10 effective
March&nbsp;1, 1996, and Amendment No.&nbsp;11 effective March&nbsp;20, 2000 to the
Shareholders&#146; Agreement, dated May&nbsp;11, 1984. (Filed as exhibits to Form&nbsp;10-K
for the year ended December&nbsp;31, 2000 on March&nbsp;7, 2001 and incorporated herein
by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.18</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment No.&nbsp;12 to the Shareholders&#146; Agreement, dated January&nbsp;31, 2001. (Filed
as an exhibit to Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2005 on August&nbsp;8,
2005 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.19</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment No.&nbsp;13 to the Shareholders&#146; Agreement, dated June&nbsp;28, 2007 (with
certain confidential information deleted therefrom). (Filed as an exhibit to
Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2007 on August&nbsp;9, 2007 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">10.20</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Product License Agreement, dated September&nbsp;30, 1985, and Technology License</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Agreement, dated September&nbsp;30, 1985, between Kirin-Amgen, Inc. and Ortho
Pharmaceutical Corporation. (Filed as an exhibit to Form&nbsp;10-Q for the quarter
ended June&nbsp;30, 2000 on August&nbsp;1, 2000 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.21</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Research, Development Technology Disclosure and License Agreement: PPO, dated
January&nbsp;20, 1986, by and between Kirin Brewery Co., Ltd. and Amgen Inc. (Filed
as an exhibit to Amendment No.&nbsp;1 to Form&nbsp;S-1 Registration Statement on March
11, 1986 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.22</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment Agreement, dated June&nbsp;30, 1988, to Research, Development, Technology
Disclosure and License Agreement: GM-CSF dated March&nbsp;31, 1987, between Kirin
Brewery Company, Limited and Amgen Inc. (Filed as an exhibit to Form&nbsp;8 amending
the Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 1988 on August
25, 1988 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.23</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Assignment and License Agreement, dated October&nbsp;16, 1986 (effective July&nbsp;1,
1986, between Amgen and Kirin-Amgen, Inc. (Filed as an exhibit to Form&nbsp;10-K for
the year ended December&nbsp;31, 2000 on March&nbsp;7, 2001 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.24</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">G-CSF United States License Agreement, dated June&nbsp;1, 1987 (effective July&nbsp;1,
1986), Amendment No.&nbsp;1, dated October&nbsp;20, 1988, and Amendment No.&nbsp;2, dated
October&nbsp;17, 1991 (effective November&nbsp;13, 1990), between Kirin-Amgen, Inc. and
Amgen Inc. (Filed as exhibits to Form&nbsp;10-K for the year ended December&nbsp;31, 2000
on March&nbsp;7, 2001 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.25</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">G-CSF European License Agreement, dated December&nbsp;30, 1986, between Kirin-Amgen
and Amgen, Amendment No.&nbsp;1 to Kirin-Amgen, Inc. / Amgen G-CSF European License
Agreement, dated June&nbsp;1, 1987, Amendment No.&nbsp;2 to Kirin-Amgen, Inc. / Amgen
G-CSF European License Agreement, dated March&nbsp;15, 1998, Amendment No.&nbsp;3 to
Kirin-Amgen, Inc. / Amgen G-CSF European License Agreement, dated October&nbsp;20,
1988, and Amendment No.&nbsp;4 to Kirin-Amgen, Inc. / Amgen G-CSF European License
Agreement, dated December&nbsp;29, 1989, between Kirin-Amgen, Inc. and Amgen Inc.
(Filed as exhibits to Form&nbsp;10-K for the year ended December&nbsp;31, 2000 on March
7, 2001 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.26</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Agreement Regarding Governance and Commercial Matters, dated December&nbsp;16, 2001,
by and among American Home Products Corporation, American Cyanamid Company and
Amgen Inc. (with certain confidential information deleted therefrom). (Filed as
an exhibit to Amendment No.&nbsp;1 to Form&nbsp;S-4 Registration Statement on March&nbsp;22,
2002 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.27</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amended and Restated Promotion Agreement, dated as of December&nbsp;16, 2001, by and
among Immunex Corporation, American Home Products Corporation and Amgen Inc.
(with certain confidential information deleted therefrom). (Filed as an exhibit
to Amendment No.&nbsp;1 to Form&nbsp;S-4 Registration Statement on March&nbsp;22, 2002 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.28</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Description of Amendment No.&nbsp;1 to Amended and Restated Promotion Agreement,
effective as of July&nbsp;8, 2003, among Wyeth, Amgen Inc. and Immunex Corporation
(with certain confidential information deleted therefrom). (Filed as an exhibit
to Form&nbsp;10-K for the year ended December&nbsp;31, 2003 on March&nbsp;11, 2004 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.29</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Description of Amendment No.&nbsp;2 to Amended and Restated Promotion Agreement,
effective as of April&nbsp;20, 2004, by and among Wyeth, Amgen Inc. and Immunex
Corporation. (Filed as an exhibit to Form&nbsp;S-4/A on June&nbsp;29, 2004 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.30</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment No.&nbsp;3 to Amended and Restated Promotion Agreement, effective as of
January&nbsp;1, 2005, by and among Wyeth, Amgen Inc. and Immunex Corporation (with
certain confidential information deleted therefrom). (Filed as an exhibit to
Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2005 on May&nbsp;4, 2005 and incorporated
herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">10.31</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Confirmation of OTC Convertible Note Hedge related to 2011 Notes, dated
February</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">14, 2006, to Amgen Inc. from Merrill Lynch International related to
the 0.125% Convertible Senior Notes Due 2011. (Filed as an exhibit to Form&nbsp;10-K
for the year ended December&nbsp;31, 2005 on March&nbsp;10, 2006 and incorporated herein
by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.32</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Confirmation of OTC Convertible Note Hedge related to 2013 Notes, dated
February&nbsp;14, 2006, to Amgen Inc. from Merrill Lynch International related to
0.375% Convertible Senior Notes Due 2013. (Filed as an exhibit to Form&nbsp;10-K for
the year ended December&nbsp;31, 2005 on March&nbsp;10, 2006 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.33</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Confirmation of OTC Convertible Note Hedge related to 2011 Notes, dated
February&nbsp;14, 2006, to Amgen Inc. from Morgan Stanley &#038; Co. International
Limited related to the 0.125% Convertible Senior Notes Due 2011 Notes. (Filed
as an exhibit to Form&nbsp;10-K for the year ended December&nbsp;31, 2005 on March&nbsp;10,
2006 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.34</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Confirmation of OTC Warrant Transaction, dated February&nbsp;14, 2006, to Amgen Inc.
from Merrill Lynch International for warrants expiring in 2011. (Filed as an
exhibit to Form&nbsp;10-K for the year ended December&nbsp;31, 2005 on March&nbsp;10, 2006 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.35</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Confirmation of OTC Warrant Transaction, dated February&nbsp;14, 2006, to Amgen Inc.
from Merrill Lynch International for warrants expiring in 2013. (Filed as an
exhibit to Form&nbsp;10-K for the year ended December&nbsp;31, 2005 on March&nbsp;10, 2006 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.36</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Confirmation of OTC Warrant Transaction, dated February&nbsp;14, 2006, to Amgen Inc.
from Morgan Stanley &#038; Co. International Limited for warrants maturing in 2011.
(Filed as an exhibit to Form&nbsp;10-K for the year ended December&nbsp;31, 2005 on March
10, 2006 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.37</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Purchase Agreement, dated May&nbsp;24, 2007, among Amgen Inc., Morgan Stanley &#038; Co.
Incorporated, Merrill Lynch, Pierce, Fenner &#038; Smith Incorporated and the
Initial Purchasers Names in Schedule&nbsp;A thereof. (Filed as an exhibit to Form
10-Q for the quarter ended June&nbsp;30, 2007 on August&nbsp;9, 2007 and incorporated
herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.38</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Purchase Agreement, dated May&nbsp;29, 2007, between Amgen Inc. and Merrill Lynch
International. (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended June&nbsp;30,
2007 on August&nbsp;9, 2007 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.39</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Collaboration Agreement, dated July&nbsp;11, 2007, between Amgen Inc. and Daiichi
Sankyo Company (with certain confidential information deleted therefrom).
(Filed as an exhibit to Form&nbsp;10-Q for the quarter ended September&nbsp;30, 2007 on
November&nbsp;9, 2007 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.40</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Credit Agreement, dated November&nbsp;2, 2007, among Amgen Inc., with Citicorp USA,
Inc., as administrative agent, Barclays Bank PLC, as syndication agent,
Citigroup Global Markets, Inc. and Barclays Capital, as joint lead arrangers
and joint book runners, and the other banks party thereto. (Filed as an exhibit
to Form&nbsp;8-K filed on November&nbsp;2, 2007 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.41</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment No.&nbsp;1, dated May&nbsp;18, 2009, to the Credit Agreement dated November&nbsp;2,
2007, among Amgen Inc., with Citicorp USA, Inc., as administrative agent,
Barclays Bank PLC, as syndication agent, Citigroup Global Markets, Inc. and
Barclays Capital, as joint lead arrangers and joint book runners, and the other
banks party thereto. (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended
June&nbsp;30, 2009 on August&nbsp;10, 2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.42</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Multi-product License Agreement with Respect to Japan between Amgen Inc. and
Takeda Pharmaceutical Company Limited dated February&nbsp;1, 2008 (with certain
confidential information deleted therefrom). (Filed as an exhibit to Form&nbsp;10-Q
for the quarter ended March&nbsp;31, 2008 on May&nbsp;12, 2008 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.43</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">License Agreement for motesanib diphosphate between Amgen Inc. and Takeda
Pharmaceutical Company Limited dated February&nbsp;1, 2008 (with certain
confidential information deleted therefrom). (Filed as an exhibit to Form&nbsp;10-Q
for the quarter ended March&nbsp;31, 2008 on May&nbsp;12, 2008 and incorporated herein by
reference.)</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">10.44</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Supply Agreement between Amgen Inc. and Takeda Pharmaceutical Company Limited
dated February&nbsp;1, 2008 (with certain confidential information deleted
therefrom). (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended March&nbsp;31,
2008 on May&nbsp;12, 2008 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.45</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Sale and Purchase Agreement between Amgen Inc. and Takeda Pharmaceutical
Company Limited dated February&nbsp;1, 2008 (with certain confidential information
deleted therefrom). (Filed as an exhibit to Form&nbsp;10-Q for the quarter ended
March&nbsp;31, 2008 on May&nbsp;12, 2008 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.46</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Variable Term Accelerated Share Repurchase Transaction dated May&nbsp;28, 2008,
between Amgen Inc. and Lehman Brothers, Inc. acting as Agent Lehman Brothers
OTC Derivatives Inc., acting as Principal. (Filed as an exhibit to Form&nbsp;10-Q
for the quarter ended June&nbsp;30, 2009 on August&nbsp;8, 2008 and incorporated herein
by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.47</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Underwriting Agreement, dated May&nbsp;20, 2008, among Amgen Inc. with Goldman,
Sachs &#038; Co. and Merrill Lynch, Pierce, Fenner &#038; Smith Incorporated, as the
representatives of the underwriters. (Filed as an exhibit to Form&nbsp;8-K on May
23, 2008 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.48</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Underwriting Agreement, dated January&nbsp;13, 2009, by and among the Company and
Goldman, Sachs &#038; Co., Merrill Lynch, Pierce, Fenner &#038; Smith Incorporated and
Morgan Stanley &#038; Co. Incorporated, as representatives of the several
underwriters named therein. (Filed as an exhibit to Form&nbsp;8-K on January&nbsp;16,
2009 and incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.49</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Master Services Agreement, dated October&nbsp;22, 2008, between Amgen Inc. and
International Business Machines Corporation (with certain confidential
information deleted therefrom). (Filed as an exhibit to Form&nbsp;10-K for the year
ended December&nbsp;31, 2008 on February&nbsp;27, 2009 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.50</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Amendment, dated December&nbsp;11, 2009, to Master Services Agreement, dated October
22, 2009, between Amgen Inc. and International Business Machines Corporation
(with certain confidential information deleted therefrom). (Filed as an exhibit
to Form&nbsp;10-K for the year ended December&nbsp;31, 2009 on March&nbsp;1, 2010 and
incorporated herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.51</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Integrated Facilities Management Services Agreement, dated February&nbsp;4, 2009
between Amgen Inc. and Jones Lang LaSalle Americas, Inc. (with certain
confidential information deleted therefrom). (Filed as an exhibit to Form&nbsp;10-K
for the year ended December&nbsp;31, 2008 on February&nbsp;27, 2009 and incorporated
herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.52</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Collaboration Agreement dated July&nbsp;27, 2009 between Amgen Inc. and Glaxo Group
Limited, a wholly-owned subsidiary of GlaxoSmithKline plc (with certain
confidential information deleted therefrom). (Filed as an exhibit to Form&nbsp;10-Q
for the quarter ended September&nbsp;30, 2009 on November&nbsp;6, 2009 and incorporated
herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.53</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Expansion Agreement dated July&nbsp;27, 2009 between Amgen Inc. and Glaxo Group
Limited, a wholly-owned subsidiary of GlaxoSmithKline plc (with certain
confidential information deleted therefrom). (Filed as an exhibit to Form&nbsp;10-Q
for the quarter ended September&nbsp;30, 2009 on November&nbsp;6, 2009 and incorporated
herein by reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">10.54</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Underwriting Agreement, dated March&nbsp;12, 2010, by and among the Company and Banc
of America Securities LLC, Barclays Capital Inc. and Morgan Stanley &#038; Co.
Incorporated, as representatives of the several underwriters named therein.
(Filed as an exhibit to Form&nbsp;8-K on March&nbsp;15, 2010 and incorporated herein by
reference.)</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">31*</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Rule&nbsp;13a-14(a) Certifications.</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">32**</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">Section&nbsp;1350 Certifications.</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">101.INS**</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">XBRL Instance Document.</DIV></TD>
</TR>
<TR valign="bottom" style="line-height: 6pt"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">&nbsp;</DIV></TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">101.SCH**</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">XBRL Taxonomy Extension Schema Document.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 12pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="91%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">101.CAL**</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">XBRL Taxonomy Extension Calculation Linkbase Document.</DIV></TD>
</TR>
<tr style="font-size:6pt"><td>&nbsp;</td></tr>

 <TR valign="bottom">
    <TD align="left" valign="top">101.LAB**</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">XBRL Taxonomy Extension Label Linkbase Document.</DIV></TD>
</TR>
<tr style="font-size:6pt"><td>&nbsp;</td></tr>
 <TR valign="bottom">
    <TD align="left" valign="top">101.PRE**</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">XBRL Taxonomy Extension Presentation Linkbase Document.</DIV></TD>
</TR>
<tr style="font-size:6pt"><td>&nbsp;</td></tr>
 <TR valign="bottom">
    <TD align="left" valign="top">101.DEF**</TD>
    <TD>&nbsp;</TD>
    <TD><DIV align="justify">XBRL Taxonomy Extension Definition Linkbase.</DIV></TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align:justify">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="2%" nowrap align="left" colspan="3">(* &nbsp;&nbsp;=  &nbsp;filed herewith)</TD>
</TR>

<tr style="font-size: 6pt"><td>&nbsp;</td></tr>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">

    <TD width="2%" nowrap align="left" colspan="3">(** = &nbsp;furnished herewith and not &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange
Act of 1934, as amended)</TD>
</TR>
</TABLE>
</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 6pt">(&#043; &nbsp;&nbsp;= &nbsp;management contract or compensatory plan or arrangement.)
</DIV>



<P align="center" style="font-size: 12pt"><!-- Folio -->54<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
